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 “If the human brain were so simple that we could understand it, we 
would be so simple that we couldn’t.” 
                                                                                                       Emerson M. Pugh
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Abstract 
 
Neuroinflammation and pro-inflammatory mediators play key roles in the pathogenesis 
of neurodegenerative diseases such as Alzheimer disease (AD). Studies have 
suggested that oestrogen has anti-inflammatory and neuroprotective activities. 
However, risks of tumour development, heart disease, stroke and blood clots 
associated with oestrogen replacement therapy limit its application in 
neurodegenerative disorders. This has switched interest to the use of alternatives such 
as the selective oestrogen receptor modulators (SERMs) and phytoestrogens which 
retain the neuroprotective effects of oestrogen with fewer side effects. Formononentin 
(FMN) is a phytoestrogen which showed significant anti-inflammatory activity through 
inhibition of nitric oxide (NO) released from lipopolysaccharide-stimulated mouse 
macrophage RAW cells. However, the ability of formononetin to produce anti-
neuroinflammatory activity in LPS-activated microglia is unknown. In addition, the 
molecular mechanisms involved in the action of the compound in neuroinflammation is 
unknown. It is also not clear if the anti-inflammatory and neuroprotective effects of 
formononetin are mediated through estrogen receptors. This study has evaluated the 
effects of formononetin on neuroinflammation in BV2 microglia. Also the roles of ERβ 
activation in the anti-inflammatory activity of formononetin in the microglia was 
investigated.  
BV2 microglia were activated with lipopolysaccharide (LPS) with or without 
formononetin (2.5, 5 and 10 µM), followed by measurement of TNFα, IL-6, nitrite and 
PGE2 levels in culture supernatants. Also, protein levels of iNOS, COX-2, total IBα, 
phospho-IBα, phospho-p65 subunit, phospho-IKKα, phospho-p38, phospho-JNK, 
phospho-ERK 1/2, phospho-MLK3, phospho-TAK1 and ERβ were detected with 
immunoblotting. A reporter gene assay was used to evaluate NF-B and ERβ 
transcriptional activation in HEK293. Electrophoretic mobility shift assay (EMSA) and 
DNA binding assays were used to examine the effect of formononetin on DNA binding 
of NF-B. HT22 neuronal cells were used to study the neuroprotective activity of 
formononetin. The role of estrogen receptor in the anti-inflammatory activity of 
formononetin was investigated with western blotting for ERα and ERβ expression in 
BV2 microglia The effect of formononetin on transcriptional activity of oestrogen-
response element (ERE) was also investigated. Small interfering RNAs (siRNAs) 
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targeted at ERβ were used to silence ERβ geneand levels of TNFα, nitrite and PGE2 
were detected in ERβ-silenced BV2 microglia, while immunofluorescence was used to 
detect NF-κB p65 subunit.  
Results show that formononetin significantly suppressed TNFα, IL-6 and IL-1β without 
affecting viability of BV2 microglia cells. Furthermore, formononetin inhibited the 
production of nitrite and PGE2, and reduced protein levels of COX-2 and iNOS in LPS-
activated microglia. In addition, formononetin prevented HTT22 neuronal toxicity 
produced by microglia-conditioned medium. Formononetin targeted NF-B activity by 
inhibiting the phosphorylation of IKKα, IBα and nuclear translocation of the p65 
subunit. The compound also suppressed NF-𝜅B/DNA binding activity in LPS stimulated 
BV2 microglia. Further results showed that formononetin inhibited p-38, JNK and 
ERK1/2 MAPKs activation by targeting upstream proteins TAK-1 and MLK3. The study 
revealed that BV2 microglia express ERβ, but not ERα. The study also demonstrated 
that formononetin increased transcriptional activity of ERE in HEK293 cells. Results 
further showed that this compound increased protein levels of ERβ in BV2 microglia. 
RNA interference experiments revealed that NF-B-mediated anti-inflammatory 
activity of formononetin was abolished following transfection of BV2 microglia with ERβ 
siRNA. Taken together, this study has demonstrated for the first time, that 
formononetin inhibits neuroinflammation in BV2 microglia , and 
neuroinflammation-mediated neurotoxicity in HT22 mouse hippocampal neurons by 
targeting upstream convergence proteins in both the NF-B and MAPK signalling 
pathways. This study also established that the ability of the compound to interact with 
microglial ERβ possibly contributes to the anti-inflammatory action of formononetin. 
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Chapter One  
Introduction
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1.1. Background 
The immune system is a complex biological system, which has a role in defending the 
body against attacks such as pathogens and their toxins. The immune system has 
three lines of defence. First, the anatomical and physiological barriers such as the 
skin, mucus and clearance mechanisms, the stomach pH and lysozymes, bacteriolytic 
tears, saliva and other secretions and the blood-brain barrier (BBB) are the first lines 
of defence the body against pathogens (Delves et al., 2000; Langman, 2014). 
The innate immune response implicates nonspecific immune defence mechanisms 
that start immediately or within hours after an antigen or chemical passes in to the 
body. Innate immunity is congenital; macrophages recognise pathogens via receptors 
pattern recognition receptors (PRRs) including toll like receptors (TLRs) and 
nucleotide oligomerization domain (NOD) receptors. Recognition of these patterns by 
macrophages initiates cellular defence mechanisms (LeClair, 2003; Han et al., 2005; 
Sterka et al., 2006; Lotze et al., 2007). The primary role of this inflammatory response 
is to eliminate foreign substances by phagocytosis. The resolution of inflammation and 
tissue repair is a second step in the innate immune response. To resolve infection or 
repair injury, the innate immune response requires the substitution of lost or damaged 
cells and restructuring of the extracellular matrix (Barton, 2008; Koenderman et al., 
2014). 
The third line of defence is acquired immunity or adaptive immunity. It is non-
congenital. The immune system reacts with antigens and the acquired immunity’s 
components learn how to attack each antigen and create a memory by generating 
specific antibodies for it. This way it can deal with the antigen if they re-attack the body 
because it learns, adapts, and remembers them (Koenderman et al., 2014). 
The central nervous system (CNS) has long been considered to be an immune 
privileged organ. This concept results from the presence of the blood-brain barrier 
(BBB), anatomophysiological barrier, and tight junctions, which are impermeable to 
antibodies and immune cells. Research in psychoneuroimmunology in the years 1980 
and 1990 have revealed more complex relationships between IS and CNS. Indeed, an 
infectious episode is accompanied by physiological and behavioural changes such as 
fever, fatigue, decreased food intake and withdrawal, grouped under the term status 
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disease (Konsman et al., 2001).. The detection of a system of innate immunity within 
the CNS has allowed a better understanding of the interactions between IS and CNS 
and the role of these interactions in the host response to infection and associated 
behavioural changes (Ransohoff et al., 2012). 
1.2. Neuroinflammation 
Neuroinflammation as a term was first used in the 1990s to describe the inflammatory 
process and its role in the pathophysiology of most neurodegenerative diseases. 
Neuroinflammation is now frequently seen as deleterious for neurological function, and 
is common to a large number of situations, from normal aging to neurological 
conditions such as neurodegenerative diseases, autoimmune diseases or epilepsy 
and stroke (Hanisch et al., 2007). The definition of the term ‘neuroinflammation’ is 
controversial. Some scientists think the term should be restricted to responses 
involving two immune cells T and B lymphocytes from the periphery (Bird et al., 2011). 
Others use a broader definition that includes activation and proliferation of microglial 
cells (Glass et al., 2010). Graeber and co-workers exclude neuroinflammation in the 
definition of immune responses involving microglial cells observed during Alzheimer's 
and Parkinson's diseases, since these conditions do not show infiltration of peripheral 
cells, so they were grouped under the term ‘microglial activation or neuroinflammtion’ 
(Graeber et al., 2011). Neuroinflammation is associated with the CNS in several 
neurodegenerative disorders such as Alzheimer's disease, multiple sclerosis, and 
Parkinson's disease (Sheng et al., 2001; McGeer et al., 2004; Block et al., 2005; Phillis 
et al., 2006). It involves activation of microglia (Perry et al., 2013) which are considered 
as the resident immune cells of the CNS. (Schwartz et al., 2013). In response to tissue 
damage or pathogen invasion there is a developing inflammatory response which is 
amided to protect the CNS and initiates tissue repair (Wyss et al., 2002). However, 
sustained inflammation or failure in normal resolution mechanisms in the brain may 
result in the production of neurotoxic factors increasing the disease states (Lull et al., 
2010; Sarma, 2014).(Figure 1.1) 
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Figure 1.1 Schematic diagram showing neuroinflammation-mediated 
neurodegeneration in the brain. 
 
 
 
 
 
 
1.3. Neuroinflammation in Alzheimer’s disease  
Alzheimer’s disease (AD) is the most common form of age-related neurodegenerative 
diseases which cause of dementia (Heneka, et al. 2015). AD is a result of changes in 
brain areas especially the cortex and hippocampus, resulting in a progressive and 
irreversible changes in the morphology and biochemistry of the brain. The symptoms 
Several factors induce neuroinflammation such as aging, dementia, stroke, brain 
injuries, obesity and local and systemic infections by activating microglia, astrocytes and 
neurons in the brain. These factors also activate immune and inflammatory cells such 
as T-cells and mast cells in the brain. Because of this activation, many proinflammatory 
and neurotoxic mediators are released and increasess expression of inflammation 
related receptor proteins in the brain. These inflammatory mediators and enhanced 
protein expressions will further increase neuroinflammation and neurodegeneration, 
which develop into progressive neurodegenerative diseases. MC=mast cells, PAR-
2=proteinase activated receptor-2, TC=T-cells, UCPs=mitochondrial uncoupling 
proteins. Modified from (Duraisamy et al., 2017) 
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of AD are characterised by memory loss, general mental dysfunction and several 
behavioural and neuropsychiatric disturbances (Morales, et al. 2014). 
The pathology of AD is based on the role of amyloid-β (Aβ) in the formation of 
extracellular amyloid aggregates which in turn results in the formation of Tau 
aggregates and neurofibrillary tangles which contribute to neuronal loss, synaptic 
dysfunction, and diseased neurons characteristic of AD (Minter et al. 2016). In 
addition, amyloid-β (Aβ) also causes an activation of microglia and astrocytes, 
resulting in the release of several pro-inflammatory cytokines, such as TNFα, IL-1β 
and IL-6 which may act directly on neurones to induce neurotoxicity and 
neurodegeneration (Guerriero et al. 2017) (Figure 1.2) . 
.    
 
Figure 1.2 Neuroinflammation in Alzheimer’s disease 
Modified from (Castellani et al., 2008) 
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1.4. . Natural compounds with anti-inflammatory effects 
The field of drug discovery has paid a lot of attention to the neuroprotective activities 
of natural compounds from traditional medicinal herbs, which have antioxidant, anti-
inflammatory, anti-apoptotic effects. 
Genistein, one of the principal active components of Soybean isoflavone, is reported 
to produce anti-inflammatory  activity in BV2 microglia cells, through inhibition of 
TLR4/NF-kB signal pathway (Zhou et al., 2014). 
Biochanin A, an O-methylated isoflavone, is a natural organic compound that has 
shown anti-inflammatory property in LPS-activated BV2 microglia through inhibition of 
mitogen-activated protein kinase (MAPK) signalling pathways (Wu et al., 2015). 
Another study has revealed that ginseng an ancient herb used in traditional Chinese 
medicine has anti-inflammatory action in LPS-activated BV2 microglia cells by 
inhibiting the release of the pro-inflammatory factors such as iNOS and COX2 (Lee et 
al., 2012) 
1.5. . Phytoestrogens 
Phytoestrogens are naturally occurring components of many plants. As the name 
suggests, they show oestrogen-like properties. A slightly broader definition also 
includes effects that suggest an oestrogen mechanism. These include binding to the 
oestrogen receptor, and induction of specific oestrogen responsive gene products 
(Sirotkin et al., 2014).  
Chemically, phytoestrogens can be classified into five groups, chalcones, flavonoids 
(flavones, flavonols, flavanones, isoflavonoids), lignans, stilbenoids, and 
miscellaneous classes as shown in figure 1.3. Particularly, isoflavonoids are a 
subgroup of flavonoids which include amongst others the chemical groups of 
isoflavones, isoflavanones, pterocarpanes, and coumestans (Michel et al., 2013; 
Sirotkin et al., 2014). 
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Figure 1.3 Molecular structures of the most ubiquitous phytoestrogens  
 (Michel et al., 2013). 
Isoflavones (3-phenylchromone derivatives) are the most-studied phytoestrogens. 
They differ from the flavones commonly found in plants only by the position of the 
linkage of chromone and phenyl ring. Isoflavones are predominantly found in legumes 
and are especially found in high amounts in soybeans. (Poluzzi et al., 2014).The most 
important isoflavones found in plants are biochanin A, daidzein, glycitein, genistein, 
and formononetin. Biochanin and formononetin are derivatives of genistein and 
daidzein with an additional methyl group (Zhao et al., 2010). 
In plants, isoflavones are usually present in glucoside form, which is the biologically 
inactive form. They  are converted to the active form by intestinal bacteria and 
enzymes (Adlercreutz et al., 1987) . 
Phytoestrogens have been reported to show many pharmacological activities. In the 
reproductive system, exposure of women to phytoestrogens in both pre- and post-
menopausal period may prevent the menopausal symptoms because of the decline in 
endogenous oestrogen levels, hot flashes and vasomotor symptoms, (Kronenberg et 
al., 2002; Branca et al., 2005; Bedell et al., 2014). Phytoestrogens have been 
therapeutically used for diminishing skin aging (Thornton, 2013). Pytoestrogens 
also play an important role in the immune system; soy phytoestrogens inhibit the 
intracellular signalling pathway related to NF-B transcription factor, activating 
inflammation and immune response (Liao et al., 2014; Shukla et al., 2015)  
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Animal experiments established the neuroprotective effect of phytoestrogens in terms 
of  their ability to prevent oxidative stress-induced degenerative changes in these 
neurons (Chao et al., 2012). 
1.5.1. Formononetin  
Formononetin (7-hydroxy-4'-methoxy isoflavone) is also known as Biochanin B. It is 
present in a number of plants like the red clover along with other phytoestrogens. It 
largely occurs in leguminous plants, particularly in beans, such as green beans, lima 
beans, soy (Jian-Hong et al., 2010). As shown in figures 1.4 and 1.5formononetin has 
a structural similarity to oestrogen (Yang et al., 2012). It shows oestrogenic effects 
(Mu et al., 2009b) and hypolipidemic properties (Siddiqui et al., 1976). Formononetin 
showed significant anti-inflammatory activity through inhibition of nitric oxide (NO) 
released from lipopolysaccharide-stimulated mouse macrophage RAW cells (Lai et al., 
2014). Also, formononetin showed antioxidant effects in vivo (Mu et al., 2009a). 
Several studies proved that formononetin has anti-cancer activity through initiation of 
growth-inhibitory, pro-apoptotic activities as well as inhibition of tumour cell invasion 
(Chen et al., 2011; Auyeung et al., 2012). Other studies revealed that formononetin 
target JNK, ERK and p38 MAPK signalling pathways to inhibit enterovirus 71 
replication (Wang et al., 2015) and produced wound healing activities (Huh et al., 
2011). 
It is reported that formononetin has potent antioxidant effects and oestrogenic effect 
(Mu et al., 2009b). Furthermore, some researchers have shown that formononetin 
protect neurons from oxidative stress and toxicity induced by L-glutamate or amyloid-
β (Occhiuto et al., 2009). However, little is known about the effects of formononetin on 
the neuroinflammation induced by LPS in microglia cells. 
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Figure 1.4 Chemical structure of formononetin. 
  
 
 
Figure 1.5 Chemical structure of 17β-Estradiol. 
 
 
 
 
 
 
 
 
 
 
 10 
 
1.6. Gap in knowledge  
The effect of formononetin in LPS activated BV2 microglia cells remains unclear. It is 
also not known if any potential inhibition of neuroinflammation by this compound would 
translate into neuroprotective activity. The molecular targets of action of this 
compound is also unclear, especially those relating to activation of microglia oestrogen 
receptors. 
1.6.1. Aim of the study 
The aim is to investigate inhibition of neuroinflammation by formononetin in LPS 
activated BV2 microglial cells. 
1.6.2. Specific objective  
Specifically, the following objectives would be achieved  
1. To investigate the effects of formononetin in LPS-activated BV2 microglia.  
2. To determine whether formononetin would protect neurons from 
neuroinflammation-mediated toxicity.  
3. To elucidate the roles of NF-B and MAPKs in the inhibition of 
neuroinflammation by formononetin.  
4.  To explore the roles played by activation of microglia oestrogen receptor beta 
(ERβ) in the anti-neuroinflammatory and neuroprotective activities of 
formononetin. 
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Chapter Two  
Inhibition of neuroinflammation and 
neuroinflammation-mediated 
neurotoxicity by formononetin
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2.1. Introduction  
Microglia, which are the local immune cells in the central nervous system (CNS), 
contribute to CNS inflammation in many pathological conditions.  
Microglia cells are not inactivated under normal conditions. However, they become 
activated following brain injury and migrate to the injured area .They also phagocytose 
cells and cellular debris. . In the process microglia, produce inflammatory mediators 
such as cytokines, chemokines, and reactive oxygen species. Even though an acute 
inflammation is beneficial after an inflammatory insult, there is evidence that excessive 
microglial activation can have damaging consequences on healthy cells such as 
neurons. 
Bacterial lipopolysaccharide (LPS) has the ability to induce microglia activation, 
leading to the release of inflammatory mediators (Thameem et al., 2007) These 
inflammatory mediators, such as TNF-α, IL-1β, IL-6 and PGE2 , play an important role 
in the pathological processes involved in neurodegeneration (Smith et al., 2012). 
Neurons are particularly susceptible to inflammation-related injury, suggesting that 
neuroprotective and anti-inflammatory agents (Hirsch et al., 2009; Singhal et al., 2015) 
may achieve the prevention of neuronal cell damage. It is widely well-known 
neuroinflammation is associated with many forms of neuronal cell damage that occurs 
in many neurological diseases and disorders, such as stroke, Alzheimer's disease and  
Parkinson's disease (Min et al., 2003; Kyoung et al., 2004). Therefore, the 
identification of agents to inhibit neuroinflammation might be an effective approach for 
the treatment of neurodegenerative diseases. 
2.2. The microglia in neuroinflammation 
An integral part of human immune defence is the microglial cells which are found in 
the CNS, where they constitute 20% of the total amount of glial population (Kreutzberg, 
1996). Following examination of the brains of adult mice, these cells were found 
extensively in the grey matter, hippocampus, olfactory telencephalon, basal ganglia 
and substantia nigra (Block et al., 2007). They have a branched structure and are 
formed in the mesodermal tissues of the CNS, from monocyte-macrophage lineage. 
Microglia cells are locomotive in ordinaryconditions; they move around and detect 
changes in their surroundings (Gao et al., 2008). If they sense any alarming situation, 
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they become activated and behave like macrophages. By functionality, the microglia 
are classified into: 
 Phagocytic phenotype, characterised by innate activation.  
 Antigen presenting phenotype, characterised by adaptive activation and the 
ability to determine the production of cytokines (Town et al., 2005). 
On activation, microglial cells undergo a morphological change i.e. changes to 
amoeboid shape accompanied with shrinking of cellular components and enlargement 
of the soma. The activated microglia are able to ingest and destroy cellular waste and 
other foreign materials. In addition, they also attract more microglia, cytokines and 
other elements that may help in microglial proliferation, by producing chemokines such 
as fractalkine/neurotactin (CX3CL1) and stromal cell–derived factor 1 (CXCL12) (Wolf 
et al., 2017). Neuroinflammation in microglial cells can be useful for recovery purposes 
as stimulating myelin repair, eliminating toxic proteins and averting neurodegeneration 
(Gao et al., 2008). However, the disruption in the inflammatory process might cause 
many problems. In any such case, several cytotoxic factors like superoxide (O2-), nitric 
oxide (NO) and tumour necrosis factor-α (TNFα) produced by activated microglia will 
lead to chronic neuroinflammation (Boche et al., 2013) .  
2.3. Microglial activation 
The concept of microglial activation has been known since the discovery of microglia 
as a source of inflammatory factors that are not normally expressed in CNS (Graeber 
et al., 1988; Graeber et al., 1990). As a defence mechanism, microglia mediate the 
immune response in the CNS because of infection, brain injury, and stress. There is a 
release of pro-inflammatory cytokines and generation of reactive oxygen species. 
These secretions of microglia are beneficial to the host as a protection from infection 
in the CNS, but they also can be harmful when inflammatory process is chronic. 
Activated microglia can be divided into two phenotypes (M1 and M2) (figure 2.1) based 
on the kind of the activator. The classic activated phenotype of microglia (M1) involved 
in the production of the pro-inflammatory cytokines such as IL-1β, iL-6, TNFα and 
reactive oxygen species. Whereas (M2) the alternatively activated microglia is an anti-
inflammatory phenotype, which release anti-inflammatory cytokines such as IL-4 and 
IL-10,as well as neurotrophic factors such as nerve growth factor (NGF) and brain-
derived neurotrophic factor (BDNF) (Doens et al., 2014). Activated microglia have 
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been detected in the CNS in most of neurodegenerative disorders, and they are 
believed to play a critical role in the development of these diseases.  
Several experimental studies have showed that the inhibition of microglial activation 
leads to reduced levels of neurotoxins and improved neuronal survival in 
neurodegenerative diseases (Tang et al., 2016).  
 
 
Figure 2.1 Microglia activation phyenotypes  
 
 
 
 
 
2.3.1. The role of toll-like receptors (TLRs) in neuroinflammation  
The toll protein receptors are pattern recognition receptors, first discovered in 
Drosophila. They were shown to be essential for determining the dorsal–ventral 
patterning during embryogenesis (Morisalo et al., 1995; Belvin et al., 1996). They also 
Microglia have two states of activation (classical activation M1 phenotype) and 
(alternative activation M2 phenotype) depending on stimulant. M1 phenotype 
produce various pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6, as well 
as superoxide, ROS and nitic oxide. These factors lead to neurotoxic response. M2 
microglia induced by IL-4/IL-13 and IL-10. M2 phenotype facilitate phagocytosis of 
cell debris and misfolded proteins and tissue repair, and support neuron survival by 
neurotrophic factors. Modified from (Carniglia et al., 2017).  
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play a critical role in the early innate immune response to invading pathogens by 
sensing microorganisms (Cherry et al., 2006; Ray et al., 2013).In the inflammation 
aspect a particular interest is in TLR4  which could be activated by lipopolysaccharide 
(LPS) component of the Gram-negative bacteria (Hanke et al., 2011) resulting in serial 
activation and phosphorylation of proteins Nuclear Factor kappa B (NFB) and 
Mitogen-Activated Protein Kinases (MAPKs). These pathways regulate a wide array 
of genes in different cell types (Smale, 2010). Some of these genes are responsible 
for the production of pro-inflammatory cytokines such as tumour necrosis factor-α 
(TNF-α), interleukin-β (IL-1β), and interleukin-6 (IL-6) which amplify the inflammatory 
response (Takeuchi et al., 2010). Furthermore, the generation of reactive oxygen or 
nitrogen species (ROS or RNS) further amplifies the process.  
2.3.1.1. Toll-like receptor 4 (TLR4)  
The innate immune receptor toll-like-receptor 4 (TLR4), localised on the surface of 
microglia, and is a first-line host defence receptor against invading microorganisms 
(Yao et al., 2013). TLR4 is expressed in the microglia and its activation produces the 
inflammatory and innate immune responses (Marsh et al., 2009; Pascual et al., 2011). 
Lipopolysaccharide (LPS) is the main component of the outer membrane of Gram-
negative bacteria bind to the CD14 and TLR4/MD2 complex leading an activation of 
TLR4 (Hyakkoku et al., 2010). 
TLR4 activation results in the activation of the myeloid differentiation protein 88 
(MyD88), the interleukin-1 (IL-1) receptor-associated kinase, the tumour necrosis 
factor (TNF) receptor-associated factor 6 (TRAF6), and the transforming growth factor-
beta-activated kinase 1 (TAK1). Subsequently, I kappa B kinase (IKK) complex is 
activated. The activated IKK complex phosphorylates I kappa Bα, which triggers its 
ubiquitination/degradation and subsequent release of nuclear factor kappa B (NF-B), 
which then translocate to the nucleus and activates the transcription of kappa B-
dependent genes, such as IL-1, IL-6, and TNF-α (Figure 2.2) (Ock et al., 2007; 
Lehnardt, 2010).  
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Figure 2.2 Schematic overview of Toll-like receptor (TLR) 4 signalling pathway.  
 
  
Lipopolysaccharide (LPS) binds to TLR4 on the cell membrane, followed by  
activation of the TNF receptor-associated factor 6 (TRAF6) which leads to  activation 
of transforming growth factor beta-activated kinase 1 (TAK1), This in turn leads to 
activation of transcription factors nuclear factor (NF)-κB and MAPKs including p38, 
JNK and ERK, and controls the expression of pro-inflammatory cytokines and other 
immune-related genes(O’Neill et al., 2000; Guo et al., 2010). 
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2.4. Roles of pro-inflammatory factors in neuroinflammation 
2.4.1. Pro inflammatory cytokines  
Pro-inflammatory cytokines are proteins which control cellular immunity and the 
inflammatory response (Borish et al., 2003; Murphy et al., 2008). IL-1β, IL-6 and TNF-
α are cytokines produced in the periphery and the CNS (typically by microglia) (Brough 
et al., 2011). These cytokines have been thoroughly investigated in studies involving 
neuroinflammation and neurodegenerative diseases (Wang & Tan, 2015; Kim et al., 
2016). 
2.4.1.1. Tumour necrosis factor (TNF-α) 
Tumour necrosis factor alpha (TNF-𝛼) is a pro-inflammatory cytokine which has been 
linked to innate immune response (Clark, 2007). The biological activities of TNF-α are 
mediated by two receptors, which though are similar structurally but are functionally 
different. These receptors are (TNFRI or p55) and (TNFRII or p75) (Vitkovic et al., 
2000). TNF-α receptors are important in host defence against pathogens (Dempsey 
et al., 2003). Most of the inflammatory responses, which are linked to TNF-α, are 
mediated by the p55 TNFRI. For example, studies of TNF-α receptor-deficient mice 
reveal that p55 plays a critical role in mediating endotoxic shock (Pfeffer et al., 1993; 
Waters et al., 2013). Consequently, a thorough understanding of TNF-α signalling 
pathway in neurodegenerative disorders would be useful in the development of 
novel bioactives in the treatment of these conditions. 
2.4.2. Interleukin-6 (IL-6) 
Interleukin-6 (IL-6, also known as IFN-β2) is involved in the pathogenesis of 
inflammatory disorders. Significant neuropathological changes in conditions such as 
multiple sclerosis (MS), Parkinson's and Alzheimer's diseases are strongly linked with 
increased IL-6 expression in the brain (Rothaug et al., 2016). It is important to note 
that IL-6 expression is regulated by transcription factors such as nuclear factor κB (NF-
κB), activator protein 1 (AP-1), cAMP response element binding protein (CREB) and 
CCAAT/ enhancer-binding protein β (C/EBPβ) (Dendorfer et al., 1994).  
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2.4.2.1. IL-1 Beta (IL-1β) 
The activation of IL-1-β is via Toll-like receptors (TLR) with the production of pro-IL-1-
β. Subsequently, pro-IL-1β is converted into the mature form via the enzyme caspase-
1(Gibson et al., 2004; Shaftel et al., 2007). 
2.4.3. Pro-inflammatory enzymes 
2.4.3.1. Cyclooxygenase (COX) 
Cyclooxygenase (COX) is the rate-limiting enzyme in the conversion of arachidonic 
acid to prostaglandins (PGs) which are mediators that play a major role in several 
physiological and pathological processes, including inflammation (Farooqui et al., 
2007). Two distinct COX isoforms are known as COX-1 and COX-2. These isoforms 
differ in mechanisms, tissue distribution and the mechanisms involved in their coupling 
to upstream and downstream proteins in the CNS (Grösch et al., 2017). COX-1 is 
constitutively expressed in most tissues, and has been shown to be responsible for 
PG synthesis in homeostasis (Phillis et al., 2006). On the other hand, COX-2 is mainly 
induced in response to inflammatory stimuli. The property of COX-2 led to the belief 
that selective inhibition of the enzyme can reduce inflammation without affecting the 
physiological functions of COX-1-derived PGs, resulting in the development of COX-2 
selective inhibitors. In terms of the microglia, COX-2 mRNA and protein as well as 
prostaglandin E2 formation were not detected in unstimulated microglia. However, 
following stimulation with lipopolysaccharide their levels and expression were elevated 
(Hoozemans et al., 2001). 
2.4.3.2. Nitric oxide synthases 
The synthesis of NO in inflammation depends on an inducible form of NO synthase 
(iNOS), which is synthesised in leucocytes, vasculature and possibly parenchymal 
cells at sites of injury, in response to cytokines or microbial products.  
2.5. Theme of this chapter 
The focus of the study in this chapter is the investigation into the possible protective 
effects of formononetin in the LPS-induced BV2 microglia inflammation. This chapter 
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also highlights the neuroprotective effect of formononetin in the 
mouse hippocampal HT22 neurons.  
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2.6. Materials and methods 
2.6.1. Materials  
The following materials were used: tissue culture flasks (75 mL), tissue culture plates 
(96-, 24- and 6-well plates), 50 ml and 15 ml centrifuge tubes, serological pipettes, 
micro-test tubes 0.5 ,1.5 ml and RNA free Eppendorf tubes 1.5 ml , 1000 ,200 and 10 
µl tips, pipetting reservoir (55 ml) were acquired from Sarstedt (Nürnbrecht, Germany). 
The supplier for the other materials like reagents, chemicals, buffers, ELISA kits, gels, 
membranes, antibodies and instruments will be described.  
2.6.2. Formononetin  
- Formononetin was obtained from Sigma-Aldrich, dissolved in DMSO, and a 
stock solution of 0.1 M frozen at -80°C. The purity of formononetin was 
confirmed using proton NMR.One milligram of formononetin was dissolved in 
DMSO-d6.NMR spectra were recorded on a Bruker Ascend 400 MHz 
spectrometer, with chemical shifts being quoted in ppm referenced relative to 
the residual solvent signal (, DMSO δ = 2.5) as shown in figure 2.3.  
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Figure 2.3 NMR spectra for formononetin which used in the whole study  
(a) 1H NMR spectra of FMN which used in the study (b)1H NMR spectra of FMN from 
different study as reference  (b) (Guo et al., 2017). 
 
2.6.3. Culture media 
Roswell Park Memorial Institute medium RPMI 1640, which already contained 
L-glutamine (2 mM) was purchased from Sigma (UK). This was supplemented with 
10% foetal bovine serum (Sigma), 100 mM sodium pyruvate (Sigma), streptomycin 
(100 U/ml) and penicillin G (100 mg/ml) (Sigma).  
Opti-MEM reduced-serum medium which is an improved Minimal Essential Medium 
(MEM) was supplemented with 5% FBS (Sigma), 100 mM sodium pyruvate (Sigma), 
streptomycin (100 U/ml) and penicillin (100 mg/ml) (Sigma). 
DMEM–Dulbecco's Modified Eagle Medium (Life Technologies) was supplemented 
with 10% FBS (Sigma), 100 mM sodium pyruvate (Sigma), streptomycin (100 U/ml) 
and penicillin G (100 mg/ml) (Sigma) 
 22 
 
2.6.4. Lipopolysaccharide 
Lipopolysaccharide (LPS) from Salmonella typhimurium (Innaxon UK) was used and 
stored at 4°C. A 100 µg/ml concentration of LPS was prepared using sterile deionised 
double distilled water just before stimulating cells and discarded after the stimulation. 
In order to identify the concentration of LPS which produces optimum activation of BV2 
microglia, cells were stimulated with different concentrations of LPS (10, 50, 100, 250, 
500 and 1000 ng/ml) followed by incubation for 24 hours. At the end of the incubation 
period, supernatant was collected. Nitrite assay was preformed to detect nitritic oxide 
production as an indicator for microglia activation. Results showed a concentration-
dependent increase in nitrite production up to 100 ng/ml of LPS (Figure 2.4).  
 
Figure 2.4  LPS concentration to stimulates BV2 
 
2.6.5. Cell culture 
2.6.5.1. BV2 cell culture 
BV2 mouse microglia cell line ICLCATL03001 was purchased from Interlab Cell Line 
Collection Banca Biologicae Cell Factory, Italy. Cells were cultured in 75 mL filter-
capped vented flasks using complete RPMI 1640 medium in a 5% CO2 incubator at 
37ºC. Culture medium was changed with fresh Complete RPMI 1640 medium every 
48 hours. Confluent cells were washed with phosphate-buffered saline (PBS) and 
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trypsinised with 0.25% trypsin-EDTA solution. RPMI medium was added to terminate 
the action of trypsin. Thereafter, cells were collected in 50 ml sterile centrifuge tubes 
and centrifuged at 1200 rpm for 5 minutes. The medium was then aspirated, and cells 
were re-suspended in fresh complete medium. The suspended cells were counted and 
sub-cultured in a new flask or seeded out at a concentration of 2 ˣ  105 cell/ml in various 
cell culture plates.   
Viability experiments using MTT assay revealed that treatment of BV2 cells with 
formononetin (2.5, 5.0 and 10 µM) in the presence or the absence of LPS did not 
induce cytotoxicity figure 2.4.   
 
Figure 2.5   Cell viability assay for different concentrations of formononetin. 
BV2 cells were treated with different concentrations of formononetin followed by 
stimulation with LPS (100 ng/ml) and incubated for 24 hours. After the incubation MTT 
assay was carried out. Results showed that formononetin at concentration of 2.5, 5 
and 10 µM did not affect cell viability whereas at a concentration of 20 µM and 40 µM, 
cell viability decreased to 80% and ~50%, respectively.  
 
In order to investigate the effect of DMSO (used as a vehicle in dissolving 
formononetin) on cell viability an MTT assay was carried out.  
Confluent cultures of BV2 microglia cells in 96-well plates were treated with DMSO 
(0.1, 0.2, 0.5, 1, 2 and 5%), and incubated for 24 hrs, followed by MTT assay. The 
results showed that the concentration of DMSO from 0.1 to 0.5% did not affect the 
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viability of BV2 microglia. However, treatment with 1% of DMSO produced toxicity to 
microglia (Figure 2.6). 
 
2.6  MTT assay for BV2 cells toxicity with DMSO. 
2.6.5.2. Mouse hippocampal neuronal cells (HT22) cell culture 
HT22 neuronal cells were obtained from Dr-Jeff Davis through the (Salk instite for 
biological studies, California,USA). These cells were derived from HT4 cells (Davis & 
Maher, 1994). HT22 cells were cultured in DMEM supplemented with 10 % FBS, 100 
U/ml penicillin and 100 mg/ml streptomycin in a 5 % CO2 incubator at 37 ºC. 
2.6.6. MTT assay for cell viability 
The MTT assay measures the reduction of yellow 3-(4, 5-dimethythiazol- 2-yl)-2, 5-
diphenyl tetrazolium bromide (MTT) in the mitochondria. The yellow colour of MTT 
solution is reduced to an insoluble coloured (dark purple) formazan product (Figure 
2.7). Cells are solubilised with an organic solvent (e.g., DMSO) and the released, 
solubilised formazan reagent is measured spectrophotometrically. Since the reduction 
of MTT can only occur in metabolically active cells , the level of activity is a measure 
of the viability of the cells. MTT viability assay was conducted to confirm that the 
different concentrations of formononetin used in the whole study were not reducing 
viability of the cells, indicating that any observed reduction in signals was not as a 
result of reduced cell numbers (Mosmann, 1983). 
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Figure 2.7 The principle of MTT assay, the water-soluble yellow MTT reduced to purple 
insoluble formazan can be solubilised in DMSO. (Abe et al., 2000). 
BV2 cells were cultured in 96 well plate for 48 hours. This was followed by medium 
change to serum-free RPMI medium. Cells were then incubated with or without LPS 
(100 ng/ml) in the absence or presence of formononetin (2.5, 5 and 10 µM) for 
24 hours. The medium was replaced with addition of 200 µl of MTT solution (0.5 
mg/ml; Sigma) to each well. The plate was then incubated for 4 hours at 37ºC. After 
incubation, 200 µl of medium was removed from each well without disturbing cells 
clusters. Therafter 150 µl of DMSO solution was added to each well to dissolve 
formazan crystals. After all the crystals had dissolved, absorbance was read at 540 
nm with a microplate reader (Tecan F50).  
2.6.7. Determination of nitrite production (Griess assay) 
The principle of the assay is based on the conversion of sulfanilic acid to a diazonium 
salt by reaction with nitrite in acid solution. The diazonium salt is then coupled to N-
(1-naphthyl) ethylenediamine, forming an azo dye (Figure 2.8) that can be quantified 
through colorimetry. 
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Figure 2.8 Principle of the Griess assay 
 
 
BV2 cells were seeded out in a 96-well plate at a density of 2 x 105 cells/ml for 48 
hours. Cells were then stimulated with LPS (100 ng/ml) in the absence or presence of 
formononetin (2.5, 5 and 10 µM) for 24 hours. Cell supernatants were collected and 
centrifuged for 5 minutes at 1500 rpm. Nitrite concentration in the culture medium was 
measured using Griess assay kit (Promega). Culture supernatants (50 µl) were added 
to a 96-well microtest plate. Thereafter, 50 µl of sulphanilamide added to the plate and 
incubated in dark for 10 minutes. Then, 50 µl of N-(1-naphthyl) ethylenediamine (NED) 
was added and incubated for 10 minutes. Absorbance was read at 540 nm in a 
microplate reader (Infinite F50, Tecan) and calculated against a sodium nitrite 
standard curve. 
2.6.8. Enzyme-linked immunosorbent assay (ELISA) 
BV2 cells were cultured in an incubator at 37ºC with 5% CO2. The cell density was 
2 x 105 cells/ml. Thereafter, the cells were pre-treated with formononetin (2.5-10 µM) 
for 30 minutes followed by stimulation with LPS (100 ng/ml) for a further 24 hours. 
Then, culture supernatants were collected and centrifuged for 5 minutes at 1500 rpm. 
The concentration of TNFα, IL-6, and IL-1β were measured using ELISA kits 
(Biolegend), according to the manufacturer’s instructions.  
The reaction of nitrite (NO2−) with Griess reagents forms an azo dye that is easily 
detected spectrophotometrically (Coneski et al., 2012). 
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Firstly, 96-well microplate was pre-coated by adding 100 µl of 1:200 diluted capture 
antibody to each well and incubated overnight at 4ºC. This was followed by adding 
200 µl of blocking buffer for 1 hour at room temperature. After blocking, 100 µl of 
standard and samples were added in triplicates and incubated at room temperature 
for 2 hours Then detection antibody was added to the plate for 1 hour, followed by 
addition of 100 μl of an Avidin-HRP solution to each well for 30 minutes. Thereafter, 
100 μl of TMB substrate was added followed by incubation in the dark for 15 minutes. 
Finally, the reaction was terminated by the addition of 100 μl of stop solution (0.1 M 
sulphuric acid) to each well. Absorbance was measured at 450 nm with a Tecan Infinite 
F50 microplate reader. The concentration of cytokines in samples was calculated from 
a standard curve. At the end of each step up to stopping the reaction, the plate was 
washed for 4 times using washing buffer.  
2.6.9. Prostaglandin E2 (PGE2) detection enzyme immunoassay (EIA) 
Enzyme immunoassay (EIA) is a reliable method for measuring levels of PGE2 in a 
culture medium. PGE2 EIA test kit operates by competition between the enzyme 
conjugate and the PGE2 in the sample for a limited number of binding sites on the 
antibody-coated plate. This approach allows for detection of low concentrations of 
PGE2 in a culture medium. 
BV2 cells were cultured at a density of 2 x 105 cells/ml in 5% CO2 incubator at 37ºC. 
Thereafter, cells were treated with formononetin (2.5-10 µM) 30 minutes prior to 
stimulation with LPS (100 ng/ml) for further 24 hours. Levels of PGE2 in culture 
supernatants were measured using an EIA kit (Arbor Assays, Ann Arbor, Michigan, 
USA). This was done by adding 50 µl of PGE2 standards and samples in triplicates to 
pre-coated 96-well plate with a PGE2 capture antibody, followed by addition of of PGE2 
conjugate (25 µl) and PGE2 antibody (25 µl). The plate was incubated at room 
temperature for 2 hours. Thereafter, plate was washed four times using washing buffer 
and100 µl of TMB substrate added to each well and incubated in dark for 30 minutes. 
The reaction then was terminated using a stop solution. Absorbance was measured in 
a microplate reader (Infinite F50, Tecan) at a wavelength of 450 nm. The concentration 
of PGE2 was calculated comparing to the standard curve.  
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2.6.10. Cell Lysis and Protein Extraction 
Cell lysis is the first step in cell fractionation and protein extraction and purification. As 
such, cell lysis opens the door to a myriad of proteomics research methods. 
2.6.10.1. Preparation of whole cell extracts 
Cell lysis buffer is used to lyse cells under non-denaturing conditions to study protein 
levels in the cell. Whole cell lysates were prepared by washing cells with ice-cold PBS, 
followed by addition of 20µl cell lysis radioimmunoprecipitation assay buffer (RIPA) 
(Cell Signaling) which contains 1 mM Phenylmethylsulfonyl fluoride (PMSF) (Sigma). 
The cells were incubated on ice for 10 minutes and sonicated for 1 minute followed by 
cold centrifugation for 15 minutes at 13500 rpm. The resulting supernatants were 
collected, quantified and stored at -80 ºC. 
2.6.10.2. Protein quantitation  
Whole cell extract was diluted with de-ionised double distilled water. Then, 5 µl of 
protein samples and standards were added to 96-well plate in duplicate. This was 
followed by adding 250 µl of Coomassie reagent, and incubation at room temperature 
for 10 minutes. Absorbance was measured at 540 nm and protein concentration was 
calculated from a protein standard curve. 
2.6.11. Immunoblotting 
Approximately 20 μg of protein were denatured by heating with 5 µl of lithium dodecyl 
sulfate (Invitrogen) and 2µl of 500 mM dithiothreitol (DTT) (Invitrogen) at 70oC for 10 
minutes. This was followed by electrophoresis on 4-12% Bis-Tris pre-cast 
polyacrylamide gels (Invitrogen) at a voltage of 200V for 35 minutes in a NuPAGE 
SDS running buffer (Fisher Scientific). Separated proteins were blotted onto a 
polyvinylidene fluoride (PVDF) membrane (Millipore) using transfer buffer (Fisher 
Scientific) for 2 hours at 25V. After transferring the protein, membranes were 
incubated in blocking buffer non-fat dry milk (Santa Cruz) for 1 hour at room 
temperature and washed three times for 10 minutes each in Tris-buffered saline (TBS) 
containing 0.1% Tween 20 (TBS-T) and 1% BSA, and incubated with the primary 
antibody (Table 2.1) which was diluted in Tris-buffered saline (TBS) containing 1% 
bovine serum albumin (BSA) overnight at 4C . Proteins were detected by incubation 
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with Alexa Fluor 680 goat anti-rabbit secondary antibody (1:10000; Life Technologies) 
at room temperature for 1 hour. Detection was done using a LICOR Odyssey Imager. 
All western blot experiments were carried out at least three times. 
Antibody supplier Host Type Dilution  
Anti-COX-2 Santa Cruz Rabbit Polyclonal 1:500 
Anti-iNOS Santa Cruz Rabbit Polyclonal 1:500 
Anti-MAP2 Santa Cruz Rabbit Polyclonal 1:500 
Anti-actin Sigma Aldrrich Rabbit Polyclonal 1:1000 
Table 2.1 Primary antibodies used with details of resources and dilution factor used. 
2.6.12. Neurotoxicity of BV2 conditioned medium 
Conditioned medium (CM) is a medium that cells have been cultured in for a period to 
allow these cells to release/ secrete proteins, cytokines and chemicals .Condition 
media is used to show that specific cell type produces certain mediators that can affect 
other cells phenotype. 
Conditioned medium-induced neurotoxicity has been used to investigate the effect of 
formononetin in neurotoxicity induced by LPS activated BV2 cells. BV2 microglia cells 
were pre-treated with formononetin (2.5–10 µM) and then stimulated with LPS (1 
µg/ml) for 24 hours. This was followed by centrifugation to obtain cell-free 
supernatants. The HT-22 hippocampal neuronal cells were serum-starved for 3 hours 
and then treated with BV2 microglial cell-conditioned medium, followed by 24-hour 
incubation. At the end of the experiment, 190 µl MTT solution (0.5 mg/ml) was added 
to each well containing HT22 neurons and incubated at 37 ºC for 4 hours. Then, 190 
µl of the medium was removed and 150 µl of DMSO solvent was added to wells to 
dissolve the formazan crystals. The plate was shaken for a few seconds to achieve 
through mixing followed by measurement of absorbance at 540 nm with a microplate 
reader. BV2 microglia culture media were also collected and levels of TNFα, NO, and 
PGE2 measured in the samples.  
2.6.13. Immunofluorescence 
BV2 cells were seeded at a density of 2 x 105 cell/ml in a 24-well plate. At confluence, 
cells were pre-treated with formononetin (10 μM) for 30 minutes followed by 
stimulation with LPS (100 ng/ml) for 24 hours, followed by collecting the supernatants 
and centrifugation. HT22 hippocampal neuronal cells were treated with BV2 microglia 
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cells-conditioned medium , followed by 24 hour incubation After incubation, cells were 
fixed with ice-cold 100% methanol at −20°C for 15 minutes and washed three times 
with phosphate buffer saline (PBS) for 5 minutes. This was followed by blocking  non-
specific binding by incubating cells in 5% BSA blocking solution (containing 10% horse 
serum in 1X TBS-T) for 60 minutes at room temperature. Thereafter, the cells were 
incubated with anti-MAP2 antibody (Santa Cruz diluted at 1:100 using 5% BSA 
blocking solution) overnight at 4°C. Following the incubation, cells were washed three 
times with PBS and incubated for 2 hours in the dark with Alexa Fluor 488-conjugated 
donkey anti-rabbit IgG secondary antibody (Life Technologies; 1:500) using 5% BSA 
blocking buffer Cells were then washed with PBS and counterstained with 4', 6-
diamidino-2-phenylindole DAPI (Invitrogen) at concentration of 100 µM for three 
minutes. Cells were rinsed with PBS, the excess buffer was removed and gold antifade 
reagent (Invitrogen) was added. Fluorescence images were acquired using EVOS® 
FLoid® cell imaging station. 
2.6.14. Statistical Analysis 
All experiments were performed at least three times and in triplicates and the statistical 
analysis was preformed using one-way analysis of variance (ANOVA). ANOVA allows 
for comparison of the mean values between all the groups. Analysis was followed by 
the post-hoc Student-Newman-Keuls test with multiple comparisons. Calculation of 
statistical analysis were done with Graph Pad Prism software version 5 (San Diego, 
US). Differences were considered significant at p<0.05. Immunofluorescence imaging 
results are representative of those obtained from three independent experiments.
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2.7. Results 
2.7.1. Formononetin did not affect BV2 cell viability  
In order to determine whether formononetin affected the viability of BV2 cells, MTT 
assay was carried out after incubating the cells with the compound for 24 hours. 
Results show that there was no significant difference in the viability of cells treated 
with formononetin (2.5, 5 and 10 μM) when compared with control (untreated) cells 
(Figure 2.7). 
 
 
Figure 2.9 Effect of formononetin on cell viability in LPS-activated BV2 microglia. 
Pre-treatment with formononetin (2.5, 5 and10 μM) did not affect the viability of BV2 
microglia stimulated with LPS. Cells were stimulated LPS (100 ng/ml) in the presence 
or absence of formononetin (2.5, 5 and10 μM) for 24 h. At the end of the incubation 
period, MTT assay was carried out on cells. 
2.7.2. Formononetin reduced the production of pro-inflammatory 
cytokines TNFα, IL-6 and IL-1β in BV2 microglia stimulated with LPS 
The release of pro-inflammatory cytokines such as TNFα, IL-6 and IL-1β is now known 
to be a major process in neuroinflammation. Consequently, an investigation was 
carried out to determine if pre-treatment with formononetin would suppress the release 
of these cytokines in LPS-activated BV2 microglia. Stimulation of the cells with LPS 
(100 ng/ml) resulted in a significant increase in the secretion of TNFα, IL-6 and IL-1β 
in comparison with unstimulated BV2 cells (Figure 2.8). However, when cells were 
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pre-treated with formononetin (2.5, 5 and 10 µM), there was a significant reduction 
(p<0.001) in TNFα production, in comparison with LPS control (Figure 2.8a). Similarly, 
increased levels of IL-6 secreted into culture supernatants was significantly (p<0.05) 
reduced by 5 and 10 µM formononetin (Figure 2.8b). Also results in (Figure 2.8c) 
showed significant reduction of the production of IL-1β (p<0.001) compared with LPS 
control. 
 
a)  
 
b)  
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c)  
 
 
Figure 2.10 Effect of formononetin on TNFα , IL-6 and IL-1β production in LPS-
activated BV2 microglia. 
Formononetin reduced TNFα (a), IL-6 (b) and IL-1β (c) production in LPS-activated 
BV2 microglia. Cells were stimulated with LPS (100 ng/ml) in the presence or absence 
of formononetin (2.5, 5 and10 μM) for 24 hours. At the end of the incubation period, 
supernatants were collected for ELISA measurements.  
 
2.7.3. Formononetin inhibited nitrite production through reduction of 
iNOS protein in LPS-activated BV2 microglia 
The effect of formononetin on nitrite production in LPS-stimulated BV2 microglia was 
evaluated. The compound dose-dependently suppressed the release of nitrite 
(p<0.001) following stimulation with LPS (Figure 2.9a). Further investigations using 
western blotting showed that formononetin (2.5, 5 and 10 µM) produced significant 
(p<0.001) suppression of elevated levels of iNOS protein following LPS stimulation 
(Figure 2.7b). These results suggest that formononetin suppressed NO production in 
LPS-activated BV2 microglia by reducing the levels of iNOS protein. 
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a)  
 
 
b)    
 
Figure 2.11 Effect of formononetin on nitric oxide (NO) and inducible nitric oxide 
(iNOS) protein expression in BV2 cells stimulated with LPS. 
Formononetin inhibited nitric oxide (NO) release (a) and inducible nitric oxide (iNOS) 
protein expression (b) in BV2 cells stimulated with LPS. BV2 cells were stimulated with 
LPS (100 ng/ml) in the presence or absence of formononetin (2.5, 5 and10 μM) for 24 
hours followed by preforming nitrite assay and iNOS western blot   
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2.7.4. Formononetin reduced PGE2 production by reducing levels of 
COX-2 protein in LPS-stimulated BV2 microglia  
The effects of pre-treatment with formononetin (2.5, 5 and10 μM) were tested on PGE2 
production in BV2 microglia which were stimulated with LPS. As shown in Figure 
2.10a, stimulation of BV2 cells produced marked elevation of PGE2 compared to cells, 
which were not stimulated. However, in the presence of formononetin (5 and10 μM) 
there was significant (p<0.001) and concentration-dependent reduction in PGE2 
production. Following results showing effects of formononetin on PGE2 production, 
further experiments were performed to determine whether its actions were mediated 
by the COX-2 enzyme. Results in Figure 2.10b show an increase in the levels of COX-
2 protein in LPS stimulated cells, when compared with unstimulated cells. Pre-
treatment with formononetin (10 μM) produced significant (p<0.001) reduction in LPS-
induced elevation in COX-2 protein expression. These results suggest that 
formononetin inhibits LPS-induced PGE2 production by suppressing the levels of 
COX-2 protein in BV2 microglia. 
 
a)  
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b)  
 
 
Figure 2.12 Effect of formononetin on PGE2 production and COX-2 protein levels in 
BV2 microglia activated with LPS. 
Formononetin attenuated PGE2 production (a), COX-2 protein expression (b), in LPS-
activated BV2 microglia. Microglia were incubated in a medium containing 
formononetin (2.5, 5 and10 μM) for 30 min and then activated with LPS (100 ng/ml) 
for 24 h. Formononetin prevents neuroinflammation-mediated HT22 neuronal death 
by regulating microglial activation. 
The neuroprotective effect of formononetin in BV2 microglia/HT22 hippocampal 
neuron co-culture was investigated. BV2 microglial cells were pre-treated with 
formononetin (2.5–10 µM) and then stimulated with LPS (1 µg/ml) for 24 hours. HT22 
cells were then exposed to conditioned media from the stimulated BV2 microglia for a 
further 24 hours. At the end of the experiment, viability of neuronal cells (a measure 
of neurotoxicity) was determined using the MTT assay for cell viability. Also, levels of 
MAP2 protein was detected by immunofluorescence and western blot.  
MTT results showed that formononetin significantly (p<0.01) increased HT-22 cell 
viability in a dose dependant manner compared to LPS control (Figure 2.11a), 
Furthermore, western blotting was performed for MAP2 protein. MAP2 belongs to a 
family of proteins known as the microtubule associated proteins and is an excellent 
marker for neuronal cells. Results show a significant increase (p ≤ 0.001) in MAP2 
expression (Figure 2.11b). These observations were confirmed by double-
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fluorescence imaging which showed an increasing in MAP2 expression in HT22 cells 
which were pre-treated with different concentrations of formononetin (Figure 2.11c). 
a)  
 
b)  
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c)  
 
Figure 2.13 Effects of formononetin on the microglia-mediated neurotoxicity.  
Mouse hippocampal HT22 cells were treated with conditioned medium (CM) from BV2 
microglia exposed to LPS (1 µg/ml) for 24 h with or without formononetin pre-
treatment. After 24-hour incubation, the cell viability of HT22 cells was assessed by 
MTT assay. LPS (1 µg/ml)-treated BV2 cells CM reduces the viability of HT22 cells. 
However, the decrease in cell viability was ameliorated by formononetin in a dose 
dependent manner(a). HT22 neuronal cultures were treated for 24 h with cell-free 
supernatant from LPS-stimulated BV2 in the absence or presence of formononetin. 
Lysates were collected and analysed for levels of MAP2 protein using immunoblotting 
(b),followed by immunofluorescence imaging for MAP2 protein (c).Formononetin 
produced concentration-dependent increase in MAP2 protein in HT22 neuronal cells. 
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2.8. Discussion  
Several lines of evidence from several studies indicate that pro-inflammatory 
cytokines, notably TNF-α, IL- 6 and IL-1β, participate in the early development of 
inflammation, and they play a crucial role in neuroinflammation. (Rubio-Perez et al., 
2012). Modulation of the pro-inflammatory cytokines production showed to prevent 
neurotoxicity (Wang & Tan, 2015) Pro-inflammatory cytokines have therefore 
appropriately received considerable attention as therapeutic targets in 
neuroinflammation (Linker et al., 2008; Lehnardt, 2010; Kim & Leonard, 2016). 
In the present study, induction of neuroinflammation with LPS in BV2 microglia 
resulted in a significant increase in the levels of TNF-α, IL-6 and IL-1β, in comparison 
with the control. However, pre-treatment with formononetin reduced LPS-induced 
elevation in the levels of these pro-inflammatory cytokines.These results provide the 
first evidence suggesting that formononetin inhibits neuroinflammation in BV2 
microglia. These results are also consistent with previous studies which showed that 
formononetin blocks allergic inflammation via suppression of pro‑inflammatory 
cytokine production (Xu et al., 2017).  
One of the most critical molecules released by activated microglia is nitric oxide (NO). 
NO produces physiological effects in neuromodulation and neurotransmission in the 
brain. However, excessive production of NO by microglia induces neuroinflammation 
and produces neuronal cell injury and death (Ghasemi et al., 2014). Nitric oxide (NO) 
is produced by the action of nitric oxide synthase (iNOS), which catalyses the reaction 
of arginine with molecular oxygen to form citrulline and NO (Ljubisavljevic et al., 2014). 
This study demonstrated that in the presence of formononetin, there was a reduction 
in nitrite production caused by LPS stimulation of BV2 microglia. It was further shown 
that suppression of nitrite production by formononetin was through reduction of 
inducible nitric oxide synthase (iNOS). Both observations provided further evidence 
on the inhibition of neuroinflammation by formononetin, and confirmed recent reports 
showing iNOS-mediated inhibition of NO production form N9 microglia cells (Zhou et 
al., 2017; Lai et al., 2017). 
The role of COX-2-mediated neurotoxicity in neurodegenerative disorders has been 
well explored (Feng et al., 2002). One of the key downstream products of COX-2 is 
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prostaglandin E2 (PGE2).COX-2 is upregulated during neuroinflammation in both the 
neurons and reactive microglia (Zarghi et al., 2012). PGE2 levels were found to be 
increased in the CSF of AD patients (Sil et al., 2016). Thus, PGE2 is considered as an 
important marker of neuroinflammation. Moreover,PGE2 mediated release of TNF-α, 
IL-1β, and nitrite may result in neuronal death (Müller et al., 2004). In this study it was 
shown that formononetin suppressed COX-2 protein expression which might explain 
its ability to reduce PGE2 production in LPS-activated BV2 microglia. 
A number of studies reported that phytoestrogens like genistein and equol inhibited 
the expression of COX-2 and reduced PGE2 levels in microglia cells (Hertrampf et al., 
2005; Subedi et al., 2017). It has also been shown that formononetin suppresses COX-
2 and PGE2 in (LPS)-stimulated mouse macrophage RAW 264.7 cells (Lai et al., 
2012). In vivo studies revealed that mRNA levels of COX-2 in the brain of the TBI rat 
was significantly down-regulated with formononetin (Li et al., 2014). These outcomes 
show that formononetin appears to exert modulatory activities on COX-2/PGE2 in 
diverse models of inflammation. These results are also consistent with the effects of 
the compound shown in the current investigation.  
In the CNS, chronic microglial activation has been linked to a persistent, continuous 
production of pro-inflammatory cytokines, interleukins and chemokines. The 
production of excessive amounts of these neurotoxic factors released by activated 
microglia has been shown to affect adjacent neurons (Lull et al., 2010). Neuronal 
cultures treated with conditioned medium from microglia cells that were stimulated with 
inflammatory agents such as LPS are a useful tool to study neuroinflammation in 
vitro(Haenseler et al., 2017).  
Encouraged by results showing that formononetin treatment resulted in a reduction in 
elevated levels of pro-inflammatory mediators in BV2 microglia following LPS 
stimulation, neuroinflammation-induced neurotoxicity experiments were carried out 
using conditioned medium from LPS-activated BV2 microglia. Results of cell viability 
experiments revealed neuroinflammation-induced neurotoxicity in HT22 hippocampal 
neurons exposed to conditioned medium from BV2 cells that were stimulated with 
LPS. Interestingly, neurotoxicity was reduced when BV2 cells were treated with 
formononetin prior to LPS stimulation, suggesting that this compound is able to 
prevent neuronal damage and death caused by excessive release of neurotoxic 
factors from microglia cells. 
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These observations were confirmed by detecting MAP2 protein expression following 
exposure of HT22 neurons to conditioned medium. It was shown that conditioned 
medium that was obtained from LPS-stimulated BV2 microglia cells reduced the 
expression of MAP2 protein in HT22 neurons, compared to unstimulated control cells, 
a phenomenon that was reversed in the presence for formononetin. MAP2 is a 
member of the microtubule-associated family which assemble neuronal microtubules 
(Ankam et al., 2015). MAP2 is a specific neuronal marker and is known to be highly 
expressed in healthy neuronal cells.  
This study has demonstrated a neuroprotective activity for formononetin.  This 
outcome is  consistent with another study showing that formononetin protected 
dopaminergic neurons against LPS-induced injury through inhibition of microglia 
activation and pro-inflammatory factors (Chen et al., 2008)These observations are 
significant as several studies revealed that neuroinflammation is linked with the 
induction of neuronal death through the release of excessive amounts of pro-
inflammatory cytokines (Zhao et al., 2013; de Pablos et al., 2014).  
In summary, this study has provided evidence showing that formononetin produces 
anti-inflammatory effects in LPS-activated BV2 microglia by targeting NO/iNOS and 
PGE2/COX2 production as well as reducing the production of pro-inflammatory 
cytokines TNFα, IL-6 and IL-1β. Also it appears that inhibition of neuroinflammation by 
formononetin may be partially responsible for its neuroprotective activity in 
neuroinflammation-induced toxicity to HT22 hippocampal neurons. It would be 
interesting to establish in future if formononetin could modulate other forms of 
neurotoxicity.. 
 
 
 
 
 
 
 
 42 
 
Chapter Three  
Cellular signalling involving Nuclear 
Factor-kappa B (NF-B) and the 
Mitogen Activated Protein Kinases 
(MAPKs) are the molecular targets of 
anti-inflammatory activity of 
formononetin in LPS activated BV2 
microglial 
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3.1. Introduction 
The activation of glial cells is accompanied by an increase in the production of 
proinflammatory cytokines such as TNF-α, IL-1β, and IL-6, NO and prostaglandin E2. 
This production is promoted by activation of inflammatory signalling pathways such as 
NF-B and MAPK, which are triggered by the toll-like receptor signalling (Walter et al., 
2007; Chen et al., 2012). The mammalian nuclear factor- kappa B (NF-B) and MAPK 
regulate a number of important processes, including neuroinflammation and immune 
responses, cell growth and survival. Moreover, NF-B and MAPK activities contribute 
to the pathology of several human diseases, including many cancers and chronic 
inflammatory diseases by controlling the production of the pro-inflammatory cytokines. 
In the previous chapter it was shown that formononetin inhibit the production of the 
pro-inflammatory cytokines IL-6, TNF-α and Il-1β and reduced the expression of iNOS 
and COX-2 which resulted in an inhibition of NO and PGE2 production. In this chapter, 
the roles of NF-B and MAPK pathways as possible molecular targets for anti-
inflammatory activity of formononetin are described. 
3.1.1. Nuclear Factor-kappa B 
Nuclear factor kappa beta (NF-) is a transcription factor that plays important roles 
in the immune system (Portou et al., 2015; Serasanambati et al., 2016) by regulating 
several gene expressions of cytokines such as IL-6, IL1β ,TNFα, (iNOS (COX-2) and  
growth factors. NF-B also plays a role in the development and the activity of a number 
of tissues including the central nervous system (Caviedes et al., 2017). Moreover, 
pathological dysregulation of NF-B is linked to inflammatory and autoimmune 
diseases as well as cancer (Tafani et al., 2013; Farh et al., 2015).  
NF-B family consists of five related transcription factors: p50, p52, RelA (p65), c-Rel 
and RelB (Dev et al., 2010).There are two signalling pathways leading to the activation 
of NF-B known as the canonical pathway (or classical) and the non-canonical 
pathway (or alternative pathway) (Gilmore, 2006) (Figure 3.1). The activation of IҡB 
kinase (IKK) complex is the common step in both cascades. There is catalytic kinase 
subunit for IҡB kinase (IKK) complex (IKKα and/or IKKβ) and the regulatory non-
enzymatic scaffold protein NEMO (NF-kappa B essential modulator also known as 
IKKɣ) (Perkins, 2007).NF-B transcription subunits gets activated by the 
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phosphorylation of IKK which is followed by phosphorylation and proteasomal 
degradation  of IB proteasome. Consequently NF-B unbinds and then  translocates 
into the nucleus to trigger the expression of target genes (Brasier, 2006). 
 
Figure 3.1 Canonical and noncanonical pathways of NF-κB activation.  
 
 
 
 
 
The canonical NF-κB pathway (left) by signals such as TLR ligands (e.g. LPS) 
activates the IKKβ subunit. Phosphorylation of IҡB proteins by IKKβ results in 
ubiquitination (Ub) of IκB and degradation. This releases NF-κB, which then enters 
the nucleus to regulate the transcription of inflammatory gene expression. The non-
canonical pathway (right) requires NIK to activate IKKα, followed by phosphorylation 
of p100 (NF-κB2). Modified from (Oeckinghaus et al., 2011). 
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3.1.2. Mitogen-activated protein kinases (MAPK) 
The mitogen-activated protein (MAPK) kinases are Ser/Thr kinases divided into tree 
subfamilies that include extracellular regulated kinase (ERK), c-Jun NH2-terminal 
kinase, also called stress activated protein kinases or SAPK (JNK) and p38 (Raman 
et al., 2007). The MAPKs are activated in response to different extracellular stimuli 
such as stress, growth factors , and pro-inflammatory cytokines (IL-1β, TNF-α) (Huang 
et al., 2010).  
MAPKs pathway consists of several phosphorylation of proteins (Tatevossian et al., 
2010). These initiate the phosphorylation of certain transcription factors such as NF-
B, signal transducers and activators of transcription protein (STAT) and nuclear factor 
of activated T cells (NFAT). Activation of these factors results in a cascade of signalling 
events that lead downstream to the activation of one or more of the MAP kinases 
(Figure 3.3). The involvement of multiple signalling proteins within a complex signalling 
network allows for regulation at various steps in the pathway and integration of signals 
from a diversity of stimuli (Cargnello et al., 2011).  
The activation of MAPK is through two steps and has three protein modules: the MAPK 
kinase kinase (MAP3K), MAPK kinase (MAP2K) and MAPK (Klip, 2009). The first step 
involves the phosphorylation of a kinase that has a dual specificity called MAP2K (or 
MAP/ERK kinase (MEK) or (MKK) by MAP3K. The second step is through 
phosphorylation of the MAPK by MKKS where MAPK is active. This phosphorylation 
is carried out by the addition of a phosphate group on Ser or Thr (Kyriakis et al., 2012). 
There are 12 MAPKs, 7 MKKS, and 14 MKK kinases were identified (Johnson et al., 
2002; Morel et al., 2004) (Figure 3.2). 
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Figure 3.2  Mitogen-activated protein kinases (MAPK) cascade.  
Modified from (Dzamko et al., 2014) 
3.1.2.1. p38 MAPK  
The protein p38 is a "sensor" of cell stress. It is made of four isoforms: p38-α  -β -γ , 
and -δ  which have 60% homology (Corrêa et al., 2012). In inflammatory cells, p38α 
form is the most expressed (Huang et al., 2010). p38 MAPK was identified for the first 
time as an activated kinase response to bacterial lipopolysaccharide (LPS) (Bode et 
al., 2012). The p38 MAPKs are activated by several extracellular stimuli such as 
cytokines (IL-1, IL-2, IL-7, IL-17, IL-18, TGF-β and TNF-α), and some pathogens or 
their products (LPS, Staphylococcal peptidoglycan, Staphylococcal enterotoxin B, 
Echovirus 1 and Herpes simplex virus 1) (Ono et al., 2000). IL-1, TNF-α  and LPS  are 
the major inflammatory stimuli inducing p38 MAPKs (Bode et al., 2012). The p38 
MAPK contributes significantly to neuroinflammation due to its role in the production 
of pro-inflammatory cytokines (Chan et al., 2017). Following stress stimulus, p38 
activates the mitogen-activated protein kinase (MAPK)-activated protein kinase 2 (MK-
2) (Duraisamy et al., 2008). Taken together, it is hypothesised that suppression of the 
p38 MAPK activation may be a therapeutic strategy in neuroinflammation (Figure 3.3). 
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3.1.2.2. C-jun N-terminal kinase (JNK) 
C-Jun N-terminal kinases (JNK) are kinases which respond to stress and are activated 
by various forms of triggers (Varfolomeev et al., 2004). JNK activation results in cell 
death through inflammation and apoptosis (Cao et al., 2004). Activation of JNK 
signalling results in pro-inflammatory cytokine production and cell death (Varfolomeev 
et al., 2004; Gao et al., 2005). JNK plays important roles in neuroinflammation (Tu et 
al., 2011), and is activated by stimuli such as pro-inflammatory cytokines (IL-1 and 
TNF-α) (Berenbaum, 2004). It has also been demonstrated to induce the expression 
of COX-2 (Geng et al., 1996; Hunot et al., 2004). 
3.1.2.3. Extracellular signal-regulated kinase (ERK) 
The first mammalian MAPKs identified was the  extracellular signal-regulated kinases 
(ERK1/ERK2) (Calvo et al., 2010). The ERKs are activated, by pro-inflammatory 
stimuli including cytokines such as TNFα, and PAMPs, such as LPS, These 
mechanisms of ERK activation play an important role in innate immunity and 
inflammation (Potapovich et al., 2011). The ERK pathway plays a major role in cell 
proliferation.However there is relatively little information on the role of ERK in 
neuroinflammation (Wuertz et al., 2012). More recent reports have suggested the role 
of MAP3K tpl2/cot in ERK-mediated LPS-induced activation of macrophages. Tumour 
progression locus 2 (Tpl2) knockout mice displayed abrogated LPS-induced ERK 
activation and TNF-α release (Kawaguchi et al., 2011). ERK activation appears to 
modulate translocation of TNF-α mRNA from the nucleus to the cytoplasm rather than 
affecting transcription or stabilisation of TNF-α mRNA (Fan et al., 2010) (Figure 3.3). 
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Figure 3.3 Simplified MAPK signaling pathways. 
 
 
 
In chapter two of this thesis, the anti-inflammatory effects of formononetin in LPS 
activated BV2 microglia was described. Furthermore, NF-ҡB and MAPK signalling 
pathways are known to be two of the most important signalling pathways responsible 
in neuroinflammation (Oh et al., 2013; He et al., 2016; Santa-Cecília et al., 2016). In 
addition, activation of both NF-B and MAPK signalling pathways results marked 
Overview of TLR-activated MAPK signalling pathway. As a result of LPS stimulation, 
activated signals go down from the TLR4 to the MAPK signalling pathways p.38 ,JNK 
and ERK1/2 . Modified from (Murshid et al., 2015) 
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production of pro-inflammatory mediators (Awada et al., 2014; Lai et al., 
2017).Therefore, the experiments described in this chapter was aimed at evaluating 
whether formononetin inhibits neuroinflammation through modulation of the NF-B 
and MAPK signalling pathways. 
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3.2. Materials and methods 
3.2.1. Cell culture 
3.2.1.1. BV2 cell culture 
This has been described in chapter two (section 2.6.5.1) 
3.2.1.2. Human embryonic kidney (HEK293) cell culture 
HEK293 cells obtained from (European Collection of Cell Cultures (ECACC) were 
grown in DMEM supplemented with 10% FBS and 2 mM glutamine. Cells were split 
1:3 when they reached 85–90% confluence using trypsin/EDTA in PBS. 
3.2.1.3. Preparation of whole cell extracts 
This has been described in chapter two (section 2.6.10.1). 
3.2.1.4. Preparation of nuclear extracts 
Nuclear extracts were prepared using EpiSeeker nuclear extraction kit (Abcam), 
according to the manufacturer’s instructions. Cells were washed with cold PBS. 
Thereafter, 20 μl of pre-extraction buffer was added to the cells and incubated on ice 
for 10 min. This was followed by centrifugation at 12000 rpm for 1 min. Then, 10 μl of 
nuclear extraction buffer was added to the resulting pellet and incubated on ice for 
15 min, followed by centrifugation at 13500 rpm for 15 min at 4Cº. The resulting 
nuclear extracts in the supernatants were collected and stored at -80Co. 
3.2.2. Protein quantitation  
The procedure for protein quantification was as described in chapter two (section 
2.6.10.2). 
3.2.3. Immunoblotting 
The procedure for immunoblotting has been described in chapter two (section 
2.6.11). The antibodies used in these studies are listed in Table 3.1. 
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Antibody supplier Host Type Dilution  
Anti-IBα Santa Cruz Rabbit Polyclonal 1:250 
Anti-phospho-IκBα Santa Cruz Rabbit Polyclonal 1:250 
Anti-IKKα Santa Cruz Rabbit Polyclonal 1:250 
Anti-phospho-IKKα Santa Cruz Rabbit Polyclonal 1:250 
Anti-phospho-p65 Santa Cruz Rabbit Polyclonal 1:500 
Anti-p.38 Santa Cruz Rabbit Polyclonal 1:500 
Anti-phospho-p38 Santa Cruz Rabbit Polyclonal 1:500 
Anti-JNK Abcam Rabbit Polyclonal 1:500 
Anti-phosho JNK Abcam Rabbit Polyclonal 1:500 
Anti-phosho ERK1/2 Abcam Rabbit Polyclonal 1:500 
Anti phospho-TAK1 Abcam Rabbit Polyclonal 1:500 
Anti-phospho MLK3 Abcam Rabbit Polyclonal 1:500 
Anti-actin Sigma Aldrrich Rabbit Polyclonal 1:1000 
 Table 3.1 Primary antibodies used with details of sources and dilution factor used. 
3.2.4. Reporter gene assays 
Genetic reporters are employed as indicators for investigating gene expression and 
cellular mechanisms linked to gene expression.(Cook et al., 2018) In this regard, a 
reporter gene is cloned with a DNA sequence of interest into an expression vector, 
which is then transfected into cells. Thereafter, an assay is performed on the cells to 
detect the presence of the reporter through a direct measurement of the reporter 
protein itself or its enzymatic activity (Figure 3.4).  
HEK293 cell line was used in this study as HEK293 cells have been  used extensively 
as an expression tool for recombinant proteins since it was generated over 25 years 
ago (Graham et al., 1977). In this study reporter gene assay were used to investigate 
the effect of formononetin on NFB activity.  
HEK293 cells were cultured in Modified Eagles medium (MEM) supplemented with 2 
mM glutamine, 10% fetal bovine serum (FBS). At confluence, the cells were sub-
cultured (at a ratio of 1:3) for 24 h before transfection. Thereafter, cells were harvested 
and re-suspended at 4 x105 cells/ml in Opti-MEM medium containing 5% FBS. Cells 
were seeded out in a solid white 96-well plates and incubated with 0.1 µg of pGL4.32 
[luc2P/NF-kB-RE/Hygro] vector (Promega, UK), using Lipofectamine® 2000 (Thermo 
Fisher Scientific) transfection reagent (diluted 1:3 in serum-free Opti-MEM) and 
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incubated for a further 16 h at 37ºC in 5% CO2 incubator. Following transfection, the 
medium was changed to Opti-MEM and cells incubated for a further 8 h. 
Transfected cells were treated with formononetin (2.5–10 µM) and incubated for 30 
min at 37ºC followed by TNFα (1 ng/ml) for 6 h. At the end of the stimulation, NF B-
mediated gene expression was measured using Dual-Glo Luciferase Assay System 
(Promega, Southampton, UK), according to the manufacturer’s instructions. 100 µl of 
luciferase assay reagent added to each well, followed by measurement of firefly 
luciferase activity. Thereafter 100 µl of Stop & Glo reagent was added to each well, 
then renilla luciferase activity was measured using FLUOstar OPTIMA Plate reader 
(BMG LABTECH), and the promoter activity calculated.  
 
Figure 3.4 Scheme for the mechanism of the dual-reporter system. 
(Modified from Bronstein et al., 1994) 
3.2.5. DNA binding assays 
Activation of NF-B results in the release of pro-inflammatory cytokines and other 
mediators involved in the neuroinflammation. LPS stimulation can induce transcription 
of several inflammatory genes through interactions of NF-B with the DNA in the 
microglia (Bellezzo et al., 1996; Hanamsagar et al., 2012; C. Xu et al., 2014). 
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Therefore, modulation of DNA binding by NF-B is a critical strategy in evaluation of 
NF-B pathway. 
3.2.5.1. Electrophoretic mobility shift assay 
Electrophoretic mobility shift assay (EMSA) principle is that proteins with different 
molecular weight will have different electrophoretic mobilities in a nondenaturing gel 
matrix. In the case of a DNA–protein complex, the presence of DNA-binding protein 
will cause the DNA to migrate in a characteristic manner, usually more slowly than the 
free DNA, and will thus cause shift in the DNA mobility visible upon detection (Figure 
2.4). 
 
Figure 3.5 The schematic illustration of electrophoretic mobility shift assays (EMSA)  
(Song et al., 2015) 
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Electrophoretic mobility shift assay was used to investigate the effect of formononetin 
on LPS-induced DNA binding of NF-B. Cultured BV2 cells were treated with 
formononetin (2.5-10 µM) for 30 minutes prior to stimulation with LPS (100 ng/ml) for 
a further 1 h. Nuclear extracts were prepared and nuclear protein (5 µg/µl) was 
incubated with IRDyeTM infrared dye end-labeled oligonucleotides containing the 
consensus binding sequence for NF-B  (5′-AGT TGA GGG GAC TTT CCC AGG C-
3′) (Licor Biosciences) in binding buffer (100 mM Tris, 500 mM KCl; pH 7.5, 6.25 mM 
MgCl2, 0.05 mM EDTA, 1% Nonidet P-40, 25 mM dithiothreitol (DTT), 2.5% tween20 
, and 1 µg/µl poly (dl.dC)) for 30 minutes on ice.This was followed by the addition of 2 
µl of orange loading dye (IR-labeled probe).The reaction samples were separated on 
native polyacrylamide gel (5% TBE, Life Technologies ). The gel was electrophoresed 
at 200 V at room temperature for approximately 1.5 hours, and imaged on the Licor 
Odyssey® Infrared Imaging System. 
3.2.5.2. ELISA-based DNA binding assay 
NF-B DNA binding ELISA kit contains 96-well plate with a specific double strand 
oligonucleotide immobilised on the well surface. NF-B in the nuclear extract binds 
specifically to this oligonucleotide, which is then quantified by adding a specific primary 
and secondary antibodies. The resulting colorimetric outcome can be quantified using 
a microplate reader (Figure 3.5). Effects of formononetin on DNA binding of NF-B 
was confirmed using an ELISA-based DNA binding assay.  
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Figure 3.6 Chart for the ELISA-based DNA binding assay principle. 
(Wild et al., 2013).  
Cultured BV2 microglia were treated with 2.5, 5 and 10 µM formononetin 30 minutes 
prior to stimulation with LPS (100 ng/ml). One hour later, nuclear extracts were 
prepared using EpiSeeker Nuclear Extraction Kit (Abcam), according to the 
manufacturer's instructions. DNA binding assay was carried on nuclear extracts using 
the TransAM NF-B transcription factor ELISA kit (Activ Motif, Belgium) according to 
the manufacturer's instructions. The ELISA kit employs a 96-well plate to which an 
oligonucleotide containing the NF-B consensus site (‘5-GGGACTTTCC-3’) has been 
immobilized. Briefly, 30 µl of complete binding buffer was added to each well, followed 
by 20 µg nuclear extract samples. The plate was covered and rocked (100 rpm) for 1 
hour at room temperature. This was followed by the addition of NF-B antibody 
(1:1000; for 1 hour) and HRP-conjugated antibody (1:1000; for 1 hour). Absorbance 
was read on a Tecan F50 microplate reader at 450 nm. 
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3.2.6. Immunofluorescence 
BV2 cells were seeded at a density of 2 x 105 cell/ml in a 24-well plate. At confluence, 
cells were pre-treated with formononetin (10 μM) for 30 minutes followed by 
stimulation with LPS (100 ng/ml) for various time points. After treatment, cells were 
fixed with ice-cold 100% methanol at −20°C for 15 minutes and washed three times 
with phosphate buffer saline (PBS) for 5 minutes. This was followed by blocking the  
non-specific binding by incubating cells in 5% BSA blocking solution (containing 10% 
horse serum in 1X TBS-T) for 60 minutes at room temperature. .Thereafter, the cells 
were incubated withanti-p65 antibody (Santa Cruz) diluted 1:100 overnight at 
4°C.Following the incubation, cells were washed three times with PBS and incubated 
for 2 hours in the dark with Alexa Fluor 488-conjugated donkey anti-rabbit IgG 
secondary antibody (Life Technologies; 1:500) using 5% BSA blocking buffer   Cells 
were then washed with PBS and counterstained with 4', 6-diamidino-2-phenylindole 
DAPI (Invitrogen) at concentration of 100µM for three minutes. Cells were rinsed with 
PBS, the excess buffer was removed and gold antifade reagent (Invitrogen) was 
added. Fluorescence images were acquired using EVOS® FLoid® cell imaging 
station. 
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3.3. Results  
3.3.1.1. Formononetin inhibits neuroinflammation through modulation of NF-B 
signalling 
To determine whether formononetin shows any general effect on NF-B-mediated 
gene transcription, a luciferase reporter gene assay was used. HEK293 cells were 
transfected with a vector bearing NF-B regulated luciferase reporter construct. The 
cells were then stimulated with TNFα (1 ng/ml) to activate NF-B gene transcription in 
the presence or absence of formononetin (2.5, 5 and 10 µM). The experiment showed 
significant levels of NF-B activation on cells stimulated with TNFα. However, cells 
treated with formononetin (2.5, 5 and10 μM) significantly (p<0.001) inhibited TNFα-
induced NF-B activation (Figure 3.6a).  
Further experiments were carried out to show that formononetin prevented LPS-
induced DNA binding by NF-B. Two different techniques were used-EMSA and 
ELISA-based DNA binding assay. BV2 cells were treated with formononetin (2.5, 5 
and10 μM) followed by stimulation with LPS (100 ng/ml) for 1 hour. At the end of the 
incubation, nuclear extracts were collected followed by an ELISA-based DNA binding 
assay. Formononetin significantly (p<0.001) inhibited DNA binding activity of NF-B 
(Figure 3.6b).  
The same nuclear extracts were used for EMSA assay. Formononetin (2.5, 5 
and10 µM) reduced NF-B DNA binding activity compared with LPS-stimulated BV2 
microglia in this assay (Figure 3.6c). All these results suggested that formononetin 
could interfere with multiple steps in the signalling pathway involving NF-B in BV2 
microglia. 
 
 
 
 
 
 
 58 
 
a)  
 
b)                                                                                        C) 
 
Figure 3.7 Formononetin inhibited NF-B activity and DNA binding of NF-B in LPS-
stimulated BV2 microglia. 
(a)TNFα-induced NF-kB-dependent gene expression in HEK 293 cells was inhibited 
by formononetin. Transfected cells were incubated with formononetin (2.5-10 µM) 
followed by stimulation with TNFα (1 ng/ml) for an additional 6 h. Luminescence was 
then measured.(b)Nuclear extracts from cells were added to 96-well plates to which 
an oligonucleotide containing the NF-B consensus site (5’-GGGACTTTCC-3’) has 
been immobilised, followed by addition of NF-B and HRP-conjugated antibodies. 
Absorbance was read on a microplate reader. (c)Nuclear extract was collected 
followed by EMSA. 
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3.3.1.2. Formononetin blocks IKK/ I kappa B phosphorylation and nuclear 
translocation of p65 in LPS-activated BV2 microglia. 
Inactive NF-B exists in the cytoplasm as a complex with inhibitor of kappa B (IBα) 
protein. Following an inflammatory stimulus such as LPS, this complex is 
phosphorylated by IB kinase (IKK), resulting in the translocation of active NF-B to 
the nucleus. In this study, the effect of formononetin on this process in LPS-activated 
BV2 microglia was studied. BV2 cells were pre-treated with formononetin (2.5, 5 and 
10 µM) for 30 min, followed by LPS (100 ng/ml) stimulation for a further 60 min. Using 
western blotting, it was observed that stimulation of BV2 microglia with LPS resulted 
in an increase in the phosphorylation of IKK compared to the unstimulated control 
cells. Whereas cells pre-treated with formononetin (2.5 µM) showed about 20% 
reduction of phosphorylated IKK compared to LPS stimulated cells .The degree of 
reduction increased to 35 % in cells treated with formononetin (5 µM) reaching 50% in 
pre-treated cells with (10 µM) formononetin.  (Figure 3.7a). Further, western blot 
experiments were performed to investigate the effect of formononetin on the 
phosphorylation of IBα. LPS stimulated BV2 cells had higher levels of phospho-IB 
compared with unstimulated control cells. However, pre-treated cells with 
formononetin (10 µM) significantly (p<0.001) inhibited LPS-induced phosphorylation 
of IҡB. This was accompanied by a concentration-dependent inhibition of IҡB 
degradation (Figure 3.7 b, c). 
Further experiments were performed to study the effects of the compound on nuclear 
translocation of the p65 sub-unit in LPS-stimulated BV2 microglia. Cells were pre-
treated with formononetin (2.5, 5 and 10 µM) for 30 minfollowed by LPS stimulation 
for 60 min. Then nuclear cell extracts were collected followed by western blot to detect 
phosphorylated p65. A significant elevation in the levels of phosphorylated p65 in LPS 
stimulated BV2 was observed in comparison with unstimulated cells. However, 
formononetin (5 and 10 µM) produced significant inhibition (p<0.001) of nuclear 
translocation of the p65 sub-unit following stimulation of the cells with LPS 
(Figure 3.7c). These observations were confirmed using immunofluorescence imaging 
which showed a decrease in p65 sub-unit in LPS-stimulated BV2 microglia which were 
pre-treated with formononetin (2.5, 5 and 10 µM (Figure 3.7 d). 
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a)  
 
b)  
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c)  
 
d)  
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e)  
 
Figure 3.8 Effect of formononetin on IKK/IҡB and nuclear translocation of p65 in LPS-
activated BV2 microglia. 
Formononetin attenuated phosphorylation of IKKα (a) as well as phosphorylation and 
degradation of IҡBα (b and c) in LPS stimulated BV-2 cells. BV2 cells were pre-treated 
for 30 minutes with formononetin (2.5-10 µM) prior to stimulation with LPS, and then 
incubated for another 1 hour. At the end of the incubation, whole cell extracts were 
collected and western blot performed to measure total and phospho-IKKα and 
phospho-IKKα, phsopho- and total IkBα. Induced p65 subunit nuclear translocation 
was significantly inhibited by formononetin in BV2 microglia cells. Microglia were 
incubated in a medium containing formononetin (2.5, 5 and10 μM) for 30 min and then 
activated with LPS (100 ng/ml) for 60 min, followed by western blot (d) Localisation of 
NF-κB p65 was visualised with fluorescence microscopy after immunofluorescence 
staining with NF-ҡB p65 antibody (green). Cells were stained with DAPI to visualize 
nuclei (blue) (e). 
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3.3.2. Inhibition of MAPKs contributed to inhibition of neuroinflammation 
by formononetin 
This study assessed the effect of formononetin on LPS-induced phosphorylation of 
p38, JNK and ERK in BV2 microglial cells. BV2 cells were treated with formononetin 
(2.5, 5.0 and 10 µM) and incubated for 30 min, followed by stimulation with LPS (100 
ng/ml), and incubation for a further 1 h. At the end of the incubation, whole cell lysates 
were collected and western blot was performed to detect p38, JNK and ERK.  
Exposure of BV2 cells to LPS for 1 h significantly increased the levels of 
phosphorylated p38 compared to unstimulated control cells. However, pre-treatment 
with formononetin (2.5, 5.0 and 10 µM) markedly (p<0.001) reduced the 
phosphorylation levels p38 compared to LPS control cells (Figure 3.8 a). 
Stimulated BV2 cell with LPS (100 ng/ml) for one hour showed a significant elevation 
in phosphorylated JNK when compared with un-stimulated cells.However pre-
treatment with formononetin (2.5, 5.0 and 10 µM) showed significant (p<0.001) 
reduction in p-JNK in LPS stimulated BV2 cells (Figure 3.8 b). Further results revealed 
that LPS (100 ng/ml) activation of BV2 microglia resulted in an increasing the 
phosphorylation of ERK1/2, whereas formononetin (2.5, 5.0 and 10 µM) significantly 
(p<0.001) supressed the activation of ERK1/2 in dose dependent manner (Figure 3.8 
c).These results demonstrate that LPS induces activation of p38, JNK and ERK; these 
effects were prevented with formononetin treatment. 
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c)  
 
Figure 3.9 Effect of formononetin on MAPK in BV2 cells stimulated with LPS. 
Formononetin inhibited LPS (100 ng/ml) induced phosphorylation of p.p38, p.JNK and 
ERK in BV2 microglia. Cells were pre-treated with formononetin (2.5-10 µM) prior to 
activation with LPS. At the end of the incubation, whole cell extracts were collected 
and western blot performed for total and phospho-p38 (a), phospho and total JNK (b) 
and phospho-ERK. 
3.3.2.1. Formononetin supresses the activation of MLK3 in LPS stimulated BV2 
cells 
Mixed-lineage protein kinase 3 (MLK3) is a member of the mitogen-activated protein 
(MAP) kinase kinase kinase which has been linked to the NF-B, as well as the 
ERK1/2, c-Jun NH2-terminal kinase (JNK), and p38 MAPK athways (Patrick et al., 
2001; Kim et al., 2004). Therefore, it becomes necessary to investigate the effect of 
formononetin on the activation of MLK3 in LPS stimulated BV2 microglia cells. LPS-
stimulated BV2 cells expressed higher levels of phosphorylated-MLK3 compared to 
unstimulated control cells. On pre-treating cells with formononetin (2.5, 5.0 and 10 
µM), a significant (p<0.001) reduction in phosphorylated -MLK3 was observed (Figure 
3.9).  
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Figure 3.10 Effect of formononetin in MLK3 phosphorylation in LPS activated BV2 
microglia. 
Formononetin inhibited LPS (100 ng/ml) -induced MLK3 phosphorylation in BV2 
microglia. Cells were pre-treated with formononetin (2.5-10 µM) in the presence or 
absence of LPS (100 ng/ml) and incubated for 30 min. Western blot was performed 
for phospho-MLK3. 
 
3.3.3. Foromononetin inhibited the activation of TAK1 on LPS stimulated 
BV2 cell. 
Activation of both  transcription factors NF-B and activating protein-1 (AP-1) 
signalling pathways is through a common upstream kinase transforming growth factor-
β-activated kinase 1 (TAK1) (Sakurai et al., 1998; Cejas et al., 2010). TAK1 was 
originally identified as a mitogen-activated kinase kinase kinase (MAP3K) activated by 
transforming growth factor-β (TGF-β) (Yamaguchi et al., 1995). However, it has been 
characterised as a key regulator in inflammatory and immune signaling pathways such 
as NF-B and MAPK (Sato et al., 2005; Sakurai, 2012; Goldmann et al., 2013). TAK-
1 can be considered as a convergent target protein activating both NF-B and MAPK 
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signalling pathways. Therefore, it was thought to investigate the effects of 
formononetin on TAK1 activation on LPS activated BV2 microglia.  
Stimulation of BV2 microglia with LPS resulted in a marked expression of TAK1 
protein, compared to un-stimulated control cells. However, cells pre-treated with 
formononetin (, 5.0 and 10 µM) showed significantly (p<0. 01) reduced levels of TAK1 
phosphorylation (Figure 3.10).  
 
 
Figure 3.11 Effects of formononetinon TAK1 phosphorylation.  
BV2 cells were pre-treated with indicated concentrations of formononetin for 30 
minutes prior to incubation of LPS (100 ng/mL) for 30 min. p-TAK1 was determined by 
western blot. Each immunoreactive band was digitised and expressed as a ratio of β-
actin levels. 
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3.4. Discussion  
NF-B plays an important role in sustaining the inflammatory response (Pugazhenthi 
et al., 2013). Based on the results highlighted in chapter two of the thesis, which 
demonstrate inhibition of neuroinflammation by formononetin, it became necessary to 
investigate whether inhibition of NF-B contributed to the molecular mechanism of 
action of the compound.  
Results with HEK293 transfected with NF-B-bearing luciferase vector plasmid 
revealed suppression of TNFα-induced activation of the NF-ҡB-driven luciferase 
expression, suggesting that this compound inhibited NF-B-dependent gene 
expression in general. Further experiments in BV2 microglia stimulated with LPS 
revealed that formononetin blocked critical steps involving IKK-mediated 
phosphorylation and degradation of IB, nuclear translocation as well as DNA binding 
of NF-B. These observations have clearly demonstrated that formononetin prevented 
the release of pro-inflammatory mediators in BV2 microglia by targeting multiple steps 
in NF-B signalling following stimulation with LPS. Formononetin was shown to 
produce similar NF-B inhibitory activity in other cells. The compound was reported to 
prevent apoptosis induced by IL-1β in the rat INS-1 cells through inhibition of NF-B 
(Wang et al., 2012). Similar NF-B inhibitory activity of the compound was reported in 
retinal ganglion cells (RGCs) (Jia et al., 2014). 
The Inflammatory process following NF-B activation has been closely linked to the 
onset of various neurodegenerative diseases, including Alzheimer’s disease (Zhao et 
al., 2014) and Parkinson’s disease (Anitua et al., 2015). Emerging evidence suggests 
that inflammatory responses contribute to the progress of AD, accelerating the course 
of the disease. Interestingly, the non-steroidal anti-inflammatory drugs (NSAIDs) used 
to reduce inflammation have been shown to inhibit the activation of NF-B in AD  
(Altinoz et al., 2004; Deardorff et al., 2017). Natural compounds could also inhibit 
neuroinflammation by inhibiting NF-B activity. Examples of such compounds are 
curcumin (Ambegaokar et al., 2003), resveratrol (Capiralla et al., 2012), pterostilbene 
(Capiralla et al., 2012), punicalagin (Xu et al., 2014), macranthoin G (Hu et al., 2014), 
and  salidroside (Gao et al., 2015). 
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The results from this study and evidence from previously published data on 
formononetin clearly demonstrated that the compound could block pro-inflammatory 
NF-B activation in many cells of the body, including brain microglia. Furthermore, 
inhibition of microglia NF-B suggested that this compound could be a useful scaffold 
for novel NF-B inhibitors for neurodegenerative disorders.  
The MAPKs signalling molecules p38, JNK and ERK1/2 play important roles in 
inflammatory processes (Kyriakis et al., 2012). Specifically, p38 MAPK signalling is 
strongly linked to neuroinflammation (Fan et al., 2013). Accumulating evidence 
indicates that p38 plays multiple roles in AD pathophysiology and that patients 
suffering from AD could benefit from p38 MAPK inhibitors (Munoz et al., 2010). Recent 
studies have demonstrated that p38 MAPK is capable of mediating neuroinflammation 
in AD. Consequently, the inhibition of p38 MAPK is proposed as a critical strategy in 
AD drug development (Lee et al., 2017). Results from this study show an inhibition in 
LPS-induced activation of p38 MAPK in BV2 microglia. This outcome showed that 
inhibition of p38 could potentially contribute to anti-neuroinflammatory activity by 
formononetin. It could also be concluded that this activity of the compound could be 
useful in AD treatment. 
Formononetin was also shown to block the activation of both JNK and ERK1/2 MAPKs 
in LPS-activated BV2 microglia. This was a significant outcome as JNK is known to 
mediate LPS-induced neuroinflammation and white matter injury (Wang, et al., 2012). 
Also, regulating ERK1/2 activation is known to be important in Aβ-induced 
neuroinflammation in BV2 microglia (Yu et al., 2017). Similar phytoestrogens have 
been reported to target JNK and ERK1/2 activation in different models (Liu et al., 2014; 
W. Wang et al., 2015; Lim et al., 2017; Park et al., 2017). 
Mixed lineage kinase 3 is expressed in immune effector cells including microglia in the 
CNS and is activated by cellular and metabolic stress (Dong et al., 2016). Inhibition of 
MLK3 is a potential strategy for inhibiting neuroinflammation (Ronkina et al., 2010), as 
it is an important upstream regulator of p38 and JNK MAPKs which have been shown 
to play major roles in neuroinflammation and neuronal apoptosis (Lin et al., 2013). 
Results showed that formononetin significantly inhibited the activation of MLK3 
induced by LPS in BV2 microglia, which might account for the effects of the compound 
on p38, and JNK MAPKs. Biochanin-A, a related compound to formononetin, was 
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previously shown to prevent UV-induced COX-2 expression by targeting MLK3 in 
Human HaCaT cells (Lim et al., 2013). These related phytoestrogens might be acting 
upstream to block events resulting in the release of inflammatory mediators. 
TAK1 is a member of the MAPK kinase kinase, which functions as an upstream 
signalling molecule of NF-𝜅B and MAPKs. Activated TAK1 complex phosphorylates 
IKK, which activates NF-𝜅B. It was therefore hypothesised that targeting TAK1 
activation might be an attractive strategy to treat inflammatory responses (Endale et 
al., 2017). In this study, LPS-induced TAK1 phosphorylation was significantly inhibited 
by formononetin. It could therefore be postulated that the suppression of LPS-induced 
TAK1 activity by formononetin might be responsible, in part, for its inhibition of both 
NF-𝜅B and MAPK signalling pathways. 
These findings demonstrated that formononetin could inhibit the production of 
pro-inflammatory factors in LPS-activated BV2 microglia through dual inhibition of 
NF-κB and MAPK signalling. This activity of the compound might be related to its ability 
to target the upstream TAK1 in the microglia (Figure 3.11). This study did not verify 
these actions of the compound in vivo. Further studies would therefore be needed to 
establish both NF-B and MAPK inhibition in different transgenic (NF-B knockout) 
models of neuroinflammation.  
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Figure 3.12 Scheme concluding the Molecular mechanisms underlying the anti-
inflammatory activities of formononetin in LPS activated BV2 microglial cells. 
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Chapter Four  
The role of oestrogen receptor beta 
(ERβ) activation in the inhibition of 
neuroinflammation by formononetin in 
LPS-activated BV2 microglia
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4.1. Introduction  
4.1.1. Oestrogen and neuroinflammation 
The role of oestrogens in various physiological and pathophysiological mechanisms is 
dependent on their ability to bind to oestrogen receptors and promote activation of 
transcription of oestrogen responsive genes (Hewitt et al., 2016; Coyoy et al., 2016). 
Two different oestrogen receptor (ER) subtypes, are known: ERα, the first ER 
discovered, and ERβ, which was discovered in 1996 (Kuiper et al., 1997; Lin et al., 
2004). The tissue distribution patterns of ERα and ERβ are quite different. ERβ is more 
highly expressed than ERα in the prostate, ovary, colon, urinary tract, and some brain 
regions (Gong et al., 2014).  
Anti-neuroinflammatory effects of oestrogens and related compounds have 
demonstrated in experimental autoimmune encephalomyelitis (EAE) and multiple 
sclerosis (MS) (Vegeto et al., 2001; Tiwari-Woodruff et al., 2007; Gold et al., 2009; 
Glass & Saijo, 2010). 
4.1.2. Mechanisms of action of oestrogen 
After diffusion through the plasma membrane, oestrogen can activate the transcription 
of their target genes by various signalling pathways, genomic or extragenomic (Figure 
4.1) (Cornil et al., 2015)  
4.1.2.1. The classic mechanism: ERE-dependent genomic transcriptional 
activity 
In the absence of a ligand, the receptor for oestrogen is in monomeric form, complexed 
with chaperone proteins, Heat Shock Proteins (HSP) HSP70 and HSP90 located in 
the nucleus or cytoplasm. Binding of a ligand results in a change in conformation of 
the receptor, which dissociates HSPs, dimerises with another receptor and transferred 
to the nucleus (Stender et al., 2010). The dimer can then bind to ERE upstream of the 
target genes and activate transcription (McKenna et al., 2002). Depending on the cell 
type and promoters involved, the receiver can then engage in a stimulatory or 
inhibitory activity vis-a-vis the expression of target genes (Tora et al., 1989). 
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4.1.2.2. Genomic transcriptional activity not related to ERE 
The oestrogen receptor is capable of inducing transcription of genes lacking ERE 
sequence, by indirect binding of the DNA, through interaction with a complex formed 
by two transcription factors fos and jun also known as AP-1 (Wu et al., 2008). This 
signalling pathway is involved in the transcription of genes such IGF-1 (Insulin-like 
Growth Factor-1). The expression of certain genes containing promoter GC-rich 
sequences bases is activated through interaction with SP1 complex (Stimulating 
Protein 1) (Hall et al., 2001).  
4.1.2.3. Independent transcriptional activity of the ligand 
In parallel with a hormone-dependent activation, the oestrogen receptor may be 
modulated by extracellular signals, in the absence of E2 such as Growth factors 
(Epidermal Growth Factor) and IGF-1 they are able to activate the receptor and induce 
expression of target genes (Ignar et al., 1995).  
4.1.2.4. Activation from a receiver located in the membrane 
Besides the genomic effects, there are effects called "non-genomic", and although 
they may be at the origin of transcriptional effects and occurring within seconds or 
minutes after the addition of E2. These effects are mediated through activation of 
kinases and phosphatases. The membrane receptor is localized in caveolae-
associated with proteins as caveolin (Evinger et al., 2005). It has been proposed that 
the location membrane receptor is permitted through post-translational modifications 
in particularly the S-palmitoylation of cysteine 447 (Marino et al., 2006). The link ligand 
involves various signalling cascades such as the activation of MAP kinases, 3-
phosphatidyl-inositol kinase (PI3K), phospholipase C (PLC) of protein kinase C (PKC), 
of endothelial NO synthase (eNOS) or the path of EGFR (Epidermal growth factor 
receptor) (Levin, 2002). 
Oestrogen is indeed able to activate the EGF receptor from stimulating of ERα 
membrane, leading to the release of EGF. The ERα addressed the cytoplasmic 
membrane is coupled to a G protein and activates, via the Src protein, the 
Metalloproteinases MMP-2, and MMP-9, which freed the heparin-binding epidermal 
growth factor (HB-EGF). The latter will then induce the phosphorylation of its receptor 
(EGFR) and thereby activate the signalling pathway ERK / MAPK. Activation of EGFR 
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induces activation cascade of kinases (Razandi et al., 2003). This is one of the non-
genomic effects of ERα (Levin, 2003). In addition to these mechanisms of action, in 
absence of E2, ERα  is capable of modulating cell growth and differentiation. For 
example, ERα inhibits neuronal growth by down-regulation of the MAPK and PI3K / 
Akt.  
 
Figure 4.1 Mechanism of action of oestrogen receptors. 
1. Classic mechanism of action (direct): after activation by the ligand receptor 
dimers bind DNA at specific sequences (ERE). 
2. Mechanism of action independent ERE (indirect): the receptor dimers bind to 
DNA via protein interactions. 
3. Mechanism of ligand-independent action: growth factors activating kinases 
that phosphorylate the receptors and attach to the DNA at specific sequences 
(ERE). 
4. Non-genomic mechanism of action localized to the membrane receptors 
activated kinases, leading to rapid changes in cytoplasmic proteins or to 
transcriptional regulation. 
Modified from (Reid et al., 2002) and (Heldring et al., 2007). 
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4.1.3. Oestrogen and selective oestrogen receptor modulation 
Some studies indicate that oestrogen produces anti-inflammatory and neuroprotective 
effects (Ramien et al., 2016). However, there is a risk of tumours, heart disease, stroke 
and blood clots associated with oestrogen treatment (Medicine, 2004). This has re-
focused in the selective oestrogen receptor modulators (SERMs) in the therapeutics 
of neurodegenerative diseases (Bernardi et al., 2003; Pullman, 2003). SERMs, such 
as tamoxifen and raloxifene, are molecules which bind with high affinity to oestrogen 
receptors (ERs), acting as oestrogen agonists in some tissue such as bone, liver, and 
uterine cells and as antagonists in others such as breast (Jordan, 2003; Wood et al., 
2003). These agonist/antagonist profiles for individual SERMs may differ also among 
brain areas (Zhou et al., 2002). Both of the known oestrogen receptors, ERα and ERβ, 
exist in microglial cells (Keller et al., 2000), and are thought to mediate classic 
receptor-mediated responses.  
Oestrogen exerts anti-inflammatory activity via ERα and ERβ on activated 
macrophages and activated microglial cells (Dodel et al., 1999; Drew et al., 2000; 
Keller et al., 2000; Vegeto et al., 2004; Lewis et al., 2008). There is a general 
agreement on the ability of oestrogens to limit the microglia proinflammatory status 
after short exposure to bacterial lysates (Kim, 2016), and viruses (Vrachnis et al., 
2014). The hypothesis of the anti-inflammatory potential of oestrogen was based 
initially on the in vitro observation that 17-estradiol prevented the morphological 
changes induced by LPS and the concomitant synthesis of proinflammatory molecules 
, such as matrix metalloproteinase 9, prostaglandin E2, iNOS with reactive oxygen 
species production (Paradkar et al., 2017).  
Phytoestrogens are a diverse group of plant-derived non-steroidal structural 
analogues of mammalian oestrogens that can bind to oestrogen receptors (ERs) and 
exert estrogenic or anti- estrogenic activities (Setchell, 1998; Andres et al., 2012). 
Interestingly, the soy isoflavones, such as daidzein and genistein, were among the 
first compounds noted to be ligands with selective affinity for ERβ (Meyers et al., 2001; 
Muthyala et al., 2004). Another study yielded a novel phytoestrogenic formulation by 
combining three phytoestrogens genistein, daidzein, and equol referred to as the 
phyto-β-SERM formulation, which exhibits an 83-fold binding selectivity for the 
oestrogen receptor subtype β (ERβ) over ERα (Zhao, 2013). The relatively selective 
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binding of phytoestrogens to ERβ indicated that they might produce clinical effects 
distinct from oestrogens by either selectively or differentially triggering ERβ-mediated 
transcriptional activation or repression pathways. 
BV2 microglia cell line naturally expresses ERβ but not ERα (Baker et al., 2004). 
These studies were designed to test the hypothesis that formononetin exerts anti-
inflammatory effects in BV2 microglia cells, specifically via interactions with ERβ. 
  
 78 
 
4.2. Materials and methods 
4.2.1. Cell culture 
4.2.1.1. BV2 cell culture 
BV2 cells were cultured as described in chapter two (Section 2.6.5.1). 
4.2.1.2. Human embryonic kidney (HEK293) cell culture 
HEK293 cells were cultured as described in chapter three (Section 3.6.1.2). 
4.2.2. Preparation of whole cell extracts 
This was carried out as described in chapter two (Section 2.6.10.1). 
4.2.3. Preparation of nuclear extracts 
This was carried out as described in chapter three (Section 3.2.4.1). 
4.2.4. Protein quantitation  
This was carried out as described in chapter two (Section 2.6.10.2). 
4.2.5. Immunoblotting 
The procedure for immunoblotting has been described in chapter two (section 2.6.11). 
The antibodies used in these studies are listed in Table 4.1. 
Antibody supplier Host Type Dilution  
Anti-ERα Abcam Rabbit Polyclonal 1:500 
Anti-ERβ Santa Cruz Rabbit Polyclonal 1:500 
Anti-phospho-p65 Santa Cruz Rabbit Polyclonal 1:500 
Anti-actin Sigma Aldrrich Rabbit Polyclonal 1:1000 
 Table 4.1Primary antibodies used with details of resources and dilution factor used. 
4.2.6. Reporter gene assays 
This procedure was similar to that described in chapter three (section 3.2.4), with some 
modifications. The vector used in this case was the Cignal ERE Reporter (luc) 
(sabiosciences). ERE reporter kit is designed to monitor the activity of oestrogen 
receptor-induced signal transduction pathways in cultured cells. 
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4.2.7. Determination of nitrite production (Griess assay). 
Griess assay was performed as described in chaper two (section 2.6.7). 
4.2.8. Enzyme-linked immunosorbent assay (ELISA) for TNF-α detection. 
This was carried out as described in chapter two (section 2.6.8). 
4.2.9. Prostaglandin E2 (PGE2) detection enzyme immunoassay (EIA). 
This was carried out as described in chapter two (section 2.6.9). 
4.2.10. Immunofluorescence 
This was carried out as described in chapter two (section 2.6.13) .In this case after the 
blocking step cells were incubated with (anti-ERα (Abcam), anti-ERβ (Santa Cruz), 
and anti-p65 antibody (Santa Cruz)) diluted 1:100 using PBS, following overnight 
incubation at 4°C.   
4.2.11. ERβ siRNA transfection 
Small interfering RNA (siRNA) is a double-stranded RNA composed of 19~22 
nucleotides. When transfected into cells, siRNAs are associated with a protein 
complex called RNA-induced silencing complex (RISC) which unwind the double-
stranded and recruits targeted mRNA leading to cleavage and subsequently degraded 
(Figure 4.2). 
RNA interference (RNAi) is the best way to effectively knock down gene expression to 
study protein function. To confirm whether oestrogen receptor beta (ERβ) contributed 
to the anti-inflammatory actions of formononetin in LPS-activated BV2 microglia, ERβ-
siRNA was used in investigations.
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Figure 4.2 mechanism of RNA interference using siRNA. 
 
 
 
 
Small interference RNA (siRNA) is incorporated into RISC, followed by unwinding of 
the double-stranded molecule by the helicase activity of RISC. The sense strand of 
siRNA is removed and the antisense strand recruits targeted mRNA, which is 
cleaved by RISC and subsequently degraded by cellular nucleases. Modified from 
(Meister et al., 2004). 
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Small interfering RNAs (siRNAs) targeted at ERβ (Santa Cruz Biotechnology) were 
used to silence ERβ gene. BV2 cells were cultured in 96 well plate at density of 
2x105/ml using antibiotic-free (penicillin and streptomycin) RPMI1640 medium, and 
incubated at 37°C in a 5% CO2 incubator until 50% confluent. Thereafter, medium was 
changed to Opti-MEM reduced serum medium (Thermo Fisher). Then, in an 
Eppendorf tube (Tube A), 2 μl of ERβ siRNA duplex were diluted into 100 μl of Opti-
MEM reduced serum medium. In another tube (Tube B), 2 μl of lipofectamine 2000 
transfection reagent (Thermo Fisher) was diluted into 100 μl of Opti-MEM reduced 
serum medium. The dilutions were mixed gently and incubated for 5 min at room 
temperature. Next, the contents of tube B were transferred to tube A to prepare the 
transfection cocktail, which was then incubated for 30 min at room temperature. Next 
200 µl of ERβ siRNA transfection cocktail was added to each well and incubated for 6 
h at 37°C. Control BV2 microglia was transfected with control siRNA duplex. Following 
transfection, media was changed in ERβ siRNA and control siRNA-transfected cells 
to complete media and incubated for a further 18 h. Thereafter, cells were treated with 
formononetin (10 μM), followed by LPS (100 ng/ml). Levels of nitrite, PGE2,andTNFα 
were measured in culture supernatants of both ERβ-silenced and control cells. In 
addition, protein expression of NFBp65 sub-unit was measured using 
immunofluorescence. Transfection efficiency was determined by preparing whole cell 
extract from both control siRNA and ERβ-siRNA-transfected BV2 cells, and western 
blot carried out to measure levels of ERβ protein. 
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4.3. Results 
4.3.1. Effect of formononetin on luciferase-mediated oestrogen-response 
element activity 
In order to investigate the effects of formononetin on ERE-reporter gene activity, 
HEK293 cells were transfected with ERE reporter plasmid (Cignal ERE Reporter (luc) 
(Sabiosciences), and then treated with formononetin (2.5, 5.0 and 10µM). Relative 
luciferase activities were shown as fold change of treated cells. Results revealed that 
in comparison with control BV2 cells treated with formononetin showed a 5~fold and 
significantly (p<0.001) increased ERE transcriptional activity when the concentration 
of the compound 10 µM (Figure 4.3) . 
 
 
Figure 4.3  Effects of formononetin in the oestrogen-response element ERE 
transcription activity  
Formononetin -induced ERE-dependent gene expression in HEK 293 cells. HEK293 
cells were transfected with ERE reporter. After 16 hours of transfection, medium was 
changed to assay medium (Opti-MEM). After 24 h cells were treated with formononetin 
(2.5, 5 and 10 µM) for 6 hours. Dual Luciferase assay was performed, and promoter 
activity values are expressed as arbitrary units using a Renilla reporter for internal 
normalization. 
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4.4.  BV2 microglia cells express high levels of ERβ compared to 
ERα 
To establish whether formononetin has a modulatory action on oestrogen receptors 
(ERα and ERβ) in BV2 microglia, whole cell lysates were analysed using 
immunobloting to detect both ERα and ERβ expression. Results in Figure 4.4a show 
that BV2 microglia expressed ~five times higher ERβ protein than ERα. The 
expression of ERβ in BV2 cells was further confirmed with immunofluorescence 
(Figure 4.4b).  
 
Figure 4.4 Oestrogen receptors ERs expression in BV2 microglia cells. 
Identification of ER proteins in BV2 cells by immunoblotting analysis using whole cell 
extract showed that BV2 microglia express five times more ERβ than ERα (a), which 
was confirmed by double-fluorescence imaging (b). 
 
a)   
b)   
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4.4.1. Effects of formononetin on ERβ expression in BV2 microglia 
To investigate if formononetin increase the level of ERβ protein in BV2 microglia, the 
cells were treated with different concentrations of the compound followed by 
immunoblotting to detect ERβ protein. Result show significant (p<0.01) increase in the 
level of ERβ protein with 5.0 and 10 µM concentrations of formononetin, compared to 
untreated cells (Figure 4.5 a). In addition, double-fluorescence imaging for ERβ 
expression in BV2 microglia treated with formononetin (2.5, 5.0 and 10 µM) showed 
an increase in the expression of ERβ compared to untreated control cells (Figure 4.5 
b).  
a)  
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b)  
 
Figure 4.5 Formononetin activate the expression of oestrogen receptor beta (ERβ) in 
BV2 microglia cells. 
(a)Formononetin increased the expression of ERβ in BV2 microglia cells. BV2 cells 
were treated with formononetin (2.5, 5.0 and 10 µM), followed by immunoblotting 
for ERβ (b) The expression of ERβ was evaluated by immunofluorescence 
analysis. 
 86 
 
4.4.2. Effects of formononetin on nitrite, PGE2 and TNFα production in the 
presence of (ERβ) siRNA in LPS-activated BV2 microglia 
In earlier experiments, it was shown that formononetin suppressed the release of pro-
inflammatory mediators NO, TNFα and PGE2 in LPS-stimulated BV2 microglia. 
Consequently, experiments were performed to find out whether ERβ contributed to 
these effects. 
The effect of formononetin (10 µM) on nitrite production in ERβ siRNA-transfected BV2 
microglia was investigated, and results show an increase in nitrite production in control 
siRNA cells stimulated with LPS compared to unstimulated control siRNA 
cells.However, control siRNA transfected BV2 cells which were pre-treated with 
formononetin (10 µM)  followed by LPS stimulation produced ~ 50% nitrite in 
comparison with cells stimulated with LPS alone. In the ERβ siRNA transfected cells, 
which were pre-treated with formononetin (10 µM) there was no inhibition of nitrite 
production, when compared with control siRNA cells treated with same concentration 
of formononetin (Figure 4.6a). These suggested that formononetin mightbe 
suppressing NO production in LPS-activated BV2 microglia through mechanisms 
linked to ERβ. 
The effects of formononetin (10 μM) on TNFα and PGE2 production were also 
evaluated in the presence and absence of ERβ gene.  
In control siRNA-transfected BV2 cells, which were stimulated with LPS there was a 
marked release of PGE2 compared with unstimulated cells. This increase was 
attenuated when cells were treated with formononetin (10µM). However, formononetin 
(10 μM) did not affect the production of PGE2 in ERβ siRNA-transfected BV2 cells 
(Figure 4.6b). 
In addition, the results revealed that formononetin inhibited the production of TNFα in 
LPS-stimulated control siRNA transfected BV2 cells, however, the same concentration 
of formononetin (10 μM) lost its ability to suppress the production of TNFα in the 
absence of ERβ when compared with control cells (Figure 4.6c). These results suggest 
that the activation of ERβ might contribute to the suppression of pro-inflammatory 
mediators in LPS-activated BV2 microglial by formononetin. 
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c)     
 
 
 
 
d)   
 
Figure 4.6 Effects of formononetin in nitrite production in the absence of oestrogen 
receptor beta (ERβ) in LPS-activated BV2 microglia. 
Formononetin attenuated nitrite,TNFα and PGE2 production in control siRNA 
LPS-activated BV2 microglia but not in the ERβ siRNA cells .Control siRNA and 
ERβ siRNA transfected BV2 microglia were incubated in medium containing 
formononetin (10 μM) for 30 min and then stimulated with LPS (100 ng/ml) for 
24 h. (a) Formononetin diminished nitrite production in the control siRNA and 
not in ERβ siRNA BV2 microglia. Formononetin did not reduce PGE2 
production (b), and TNFα (c), in ERβ siRNA LPS-activated BV2 microglia. (d) 
Western blot showing ER-β siRNA transfection efficiency. 
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4.4.3. Effects of formononetin in localisation of NF-B p65 in the absence 
of oestrogen receptor beta (ERβ) in LPS-activated BV2 microglia. 
In order to understand whether ERβ contributed to the NF-B inhibitory activity of 
formononetin in LPS-activated BV2 microglia, immunofluorescence experiments were 
carried out on cells ,which were transfected with control siRNA or ERβ siRNA followed 
by treatment with formononetin (10 µM) for 30 min, and then stimulated with LPS (100 
ng/ml) for 60 min. At the end of the incubation, cells were stained with antibodies anti-
NF-B p65 antibody. As shown in Figure 4.7, immunofluorescence images revealed 
that NF-B p65 was sequestered in the cytoplasm (untreated panel). Furthermore, 
nuclear accumulation of NF-B p65 was markedly induced after stimulation with LPS 
(LPS panel). However, LPS-induced translocation of NF-B p65 was abolished after 
pre-treating the cells with formononetin (10 µM) (formononetin panel). On transfecting 
cells with ERβ siRNA, there was a marked reversal of the anti-inflammatory effect of 
formononetin on nuclear translocation of NF-
lls 
(Formononetin ERβsiRNA panel). 
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Figure 4.7 Effects of formononetin in localization of NF-κB p65 in the absence of 
oestrogen receptor beta (ERß) in LPS-activated BV2 microglia. 
Localization of NF-κB p65 was visualised with fluorescence microscopy after 
immunofluorescence staining with NF-κB p65 antibody (green). Cells were stained 
with DAPI to visualize nuclei (blue). Results are representative of those obtained from 
three independent experiments. 
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4.5. Discussion  
Some studies showed that the biological actions of formononetin are similar to that of 
oestrogen (Howes et al., 2002; Wang & Han, 2012). Consequently, the hypothesis in 
this chapter was to establish a link between the anti-inflammatory activities of the 
compound in BV2 microglia and its ability to modulate the activity of microglial 
oestrogen receptor. 
Experiments conducted with HEK293 in this study revealed that formononetin 
activated oestrogen response element dependent transcription. These results suggest 
that oestrogen responses was potentiated by formononetin through one of the two 
oestrogen receptors (ERα or ERβ). 
To establish whether formononetin has a modulatory action on protein levels of 
oestrogen receptors in the microglia, firstly the interest was to define the subtype of 
oestrogen receptors in BV2 microglia. Interestingly, the results showed that BV2 
microglia expressed ERβ oestrogen receptor rather than ERα. This was consistent 
with earlier reports showing that oestrogen reduced production of pro-inflammatory 
mediators from BV2 microglia through interactions with ERβ (Baker et al., 2004; Wu 
et al., 2013).  
These observations were consistent with results which showed that ERβ was 
implicated in cell survival in the developing and aging brain, and that ERβ knock-out 
mouse developed major brain malformations due to neuronal loss during ageing 
(Wang et al., 2003). Furthermore, ERβ has been reported to be localised to the 
mitochondria of many cells including neurons, and has been suggested to play a role 
in neuroprotection (Yang et al., 2004). Interestingly, studies in primary astrocyte 
revealed that compounds which bind ERβ are effective in preventing the release of 
pro-inflammatory cytokines (Lewis et al., 2008), further suggesting that this receptor 
has a potential role in neuroprotection. 
Having established in this study that the ERβ subtype of oestrogen was expressed in 
BV2 microglia, further experiments were conducted and revealed that formononetin 
increased the levels of ERβ protein in BV2 microglia. Several studies have 
demonstrated that some phytoestrogens, such as daidzein and genistein, have been 
shown to be ligands at ERβ (Meyers et al., 2001; Muthyala et al., 2004). In trustingly, 
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studies in both in vitro cell cultures and in vivo animal models revealed that the phyto-
β-SERM formulation (genistein, daidzein,and equol) produced an 83-fold binding 
preference for ERβ over ERα and showed neuroprotection in the brain, while being 
devoid of feminising activity as seen with non-selective estrogenic compounds such 
as 17β-oestradiol in the reproductive system (Zhao et al., 2009; Zhao, 2013).  
Following the observations which established that formononetin increased ERβ 
protein in BV2 microglia, it became necessary to determine the role played by the 
receptor in the earlier observed showing inhibition of neuroinflammation by the 
compound in BV2 microglia (Chapters 2 and 3). Results revealed that inhibition of 
neuroinflammation by formononetin was clearly lost in the absence of ERβ gene. 
Further investigations revealed that ERβ-dependent inhibition of neuroinflammation 
by formononetin was possibly related to cross talk between ERβ and NF-B.Further 
investigations revealed that ERβ-dependent inhibition of neuroinflammation by 
formononetin was possibly related to cross talk between ERβ and NF-кB.  
Studies have shown that ERβ functions as a gate-keeper for NF-кB signalling by 
repressing its expression and nuclear translocation, thus regulating its signalling in 
prostate cancer (Mak et al., 2015). While a regulatory role of ERβ on NF-кB signalling 
in the microglia is unclear, it would appear from the data generated in this study that 
the ability of formononetin to affect the nuclear accumulation of NF-кB depends on 
some sort of interaction with ERβ. Interestingly, a recent study showed that the seed 
extract of Cicer microphyllum (which contains biochanin A, formononetin and 
genistein) produced ERβ-mediated neuroprotective activity in Sprague Dawley rats 
(Sharma et al., 2017). The exact nature of the interactions between ERβ and NF-кB 
therefore needs further investigation. Furthermore, it would be interesting to discover 
the exact step in the NF-кB signalling pathway, that is negatively affected by ERβ, as 
this would further our knowledge on identifying novel oestrogenic compounds in 
neuroinflammation and/or neurodegeneration. 
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Chapter Five  
General discussion and conclusion 
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5.1. Discussion  
Recent studies have clearly shown that oestrogen-like compounds, which inhibit 
neuroinflammation, provide therapeutic opportunities in neurodegenerative disorders 
like AD. This study investigated the inhibition of neuroinflammation by formononetin in 
BV2 microglia stimulated with LPS, and found that the compound suppressed 
production of the pro-inflammatory cytokines TNFα, IL-6 and IL-1β from the cells. 
Results also demonstrated an attenuation of iNOS-mediated NO and COX-2-mediated 
PGE2 production from LPS-activated BV2 microglia. These results suggest that 
formononetin prevents neuroinflammation resulting from stimulating BV2 microglia 
with LPS. It also showed that pre-treatment of BV2 microglia with formononetin 
prevented microglia conditioned medium-induced neurotoxicity in HT22 hippocampal 
neurons, further suggesting that the anti-inflammatory activity of this compound could 
be useful in neuroinflammation-mediated neurodegeneration. 
Neuroinflammation has been strongly linked to the aetiopathogenesis of 
neurodegenerative disorders such as AD (Leyns et al., 2017) and PD (Kaur et al., 
2017). While it is widely recognised that diverse neuroinflammatory signals contribute 
to the pathogenesis of these conditions, results from this research suggest that the 
anti-inflammatory action of formononetin could be exploited in AD and PD 
therapeutics. Previously, formononetin isolated from various natural sources has been 
reported to have inhibitory effects on LPS-stimulated nitric oxide release in LPS-
stimulated RAW 264.7 cells (Lai et al., 2013) as well as pro-inflammatory cytokine 
production in bone marrow-derived dendritic cells (W. Li et al., 2014). Furthermore, 
formononetin was reported to inhibit both TNFα and NO production from neuron-glia 
cultures and microglia-enriched cultures (Chen et al., 2008). This study confirmed 
these results on anti-inflammatory effects of formononetin in peripheral inflammatory 
cells, and showed for the first time that the compound blocks the production of a variety 
of pro-inflammatory mediators and proteins in BV2 microglia stimulated with LPS. 
It is now widely accepted that the transcription factor, NF-B plays a significant role in 
neuroinflammation and neurodegeneration. Furthermore accumulating evidence 
suggests that disease modifying drugs for neurodegenerative disorders which inhibit 
neuroinflammation act by inhibiting NF-κB activation either directly or indirectly 
(Srinivasan et al., 2015). Consequently, the molecular mechanism of 
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anti-neuroinflammatory action of formononetin in BV2 microglia was elucidated by 
investigating its effects on important steps in the NF-B signalling pathway. 
Firstly, a reporter gene assay results showed that formononetin inhibited the 
transcriptional activity of NF-B in general. It was further established that in LPS-
stimulated BV2 microglia, formononetin inhibited critical steps involving IKK-mediated 
phosphorylation and degradation of IB, nuclear translocation as well as DNA binding 
of NF-B. 
Several studies have reported NF-B inhibitory activity of formononetin in various 
cellular models. Inhibition of IL-1β-induced NO/iNOS and apoptosis in INS1 pancreatic 
beta cells by formononetin has been attributed to its ability to inhibit the activation of 
NF-B (Wang, 2012). Inhibition of H2O2-induced apoptosis in retinal ganglion cells by 
formononetin has also been linked to inhibition of NF-B activation (Jia et al., 2014). 
Furthermore formononetin was reported to inhibit NF-B signalling pathway in bone-
marrow-derived macrophages stimulated with RANKL (Huh et al., 2014). Biochanin A 
is a closely related phytoestrogen to formononetin which has been reported to inhibit 
neuroinflammation in the microglia (Chen et al., 2007; Wu et al., 2015). However, this 
is the first report showing inhibition of neuroinflammation through NF-B signalling 
pathway in LPS-activated microglia by formononetin, and provides further evidence 
on the anti-neuroinflammatory potential of the compound. 
Mitogen-activated protein kinases MAPK signalling pathways have been shown to 
regulate diverse biological functions such as proliferation, differentiation , apoptosis 
and inflammation in various cell types (Kyriakis et al., 2012). The role of (MAPKs) in 
neuroinflammation and neurodegenerative diseases is well established (Munoz et al., 
2010). The major MAPK pathway subfamilies involved in the regulation of COX-2, 
iNOS and cytokine synthesis in LPS activated microglia are signalling proteins such 
as p38 MAPK, extracellular signal regulated kinases (ERK1/2) and c-jun-N terminal 
kinase (JNK) (Bhatia et al., 2017). 
The phosphorylation of p38 MAPK induces the expression of proinflammatory 
molecules and is one of the important signaling pathways during inflammation (Chaves 
et al., 2013; Swaroop et al., 2016). Phytoestrogens have been shown to regulate the 
activation of p38 MAPK in different cell lines (Sobenin et al., 2016; Maxwell et al., 
2017). Also several studies have suggested that some phytoestrogens block the 
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phosphorylation of p38 MAPK in LPS-activated BV2 microglia (Kang et al., 2014; Wu 
et al., 2015). These findings were confirmed in this study, which demonstrated that 
formononetin produced significant inhibition of p38 phosphorylation in LPS-activated 
BV2 microglia. 
Activation of MAPKs in microglia leads to the phosphorylation of the transcription 
factor, cJun, which contributes to the activation of microglia via the transcription of its 
target genes TNFα, IL-1β, COX-2 and MCP-1 (Waetzig et al., 2005). Furthermore, 
JNK has been implicated in the pathogenesis of various neurodegenerative diseases 
such as Parkinson's disease (Brecht et al., 2005) and Alzheimer's disease (Colombo 
et al., 2007). This study has demonstrated that formononetin inhibits the 
phosphorylation of JNK in LPS-activated BV2 microglia. The outcome of this study is 
consistent with a recent study which showed that a phytoestrogen genistein protects 
PC12 cells from Aβ25–35 induced neurotoxicity by inhibiting JNK activation (You et 
al., 2017). Another study showed that Biochanin A attenuates LPS-induced pro-
inflammatory responses and inhibits the activation of the JNK in BV2 microglial cells 
(Wu et al., 2015). 
There are numerous reports demonstrating that phosphorylation of ERKs, is 
necessary for up-regulation of iNOS and COX-2 in LPS-stimulated BV-2 cells (Oh et 
al., 2009; Kim et al., 2013), Kaempferol a phytoestrogen acts through ERK/MAPKs to 
elicit protection in a model of neuroinflammation in BV2 microglial cells (Park et al., 
2011). This study showed that formononetin inhibited the phosphorylation of ERK1/2 
in LPS-activated BV2 microglia. Mixed-lineage protein kinase 3 (MLK3) has been 
associated in multiple signaling cascades, including the extracellular signal-regulated 
kinase, c-Jun NH2-terminal kinase (JNK), and p38 MAP kinase pathways (Patrick et 
al., 2001; Kim et al., 2004). Inhibition of MLK3 is a potential strategy for treatment of 
neuroinflammation (Ronkina et al., 2010). This study proved that formononetin 
modulates the activation of MLK3, an action which may account for its impact on 
downstream targets, JNK and p38. 
Transforming growth factor b-activated kinase 1 (TAK1) a member of the MAPK kinase 
kinase functions as an upstream signalling molecule of NF-𝜅B and MAPKs. Activated 
TAK1 complex phosphorylates IKK, which activates NF-𝜅B. It is thought that targeting 
TAK1 activation may be an attractive strategy to treat inflammatory responses (Endale 
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et al., 2017). Results of this study suggest that formononetin blocked TAK1 activation 
during neuroinflammtion, which explains its dual activities on both NF-𝜅B activation 
and MAPKs pathways. 
Several studies have suggested anti-neuroinflammatory actions of oestrogens in 
animal models and in vitro. It has also been suggested that this action may account 
for their neuroprotective activity in the brain. However, the risk of tumours and 
associated with oestrogen has led to investigations of neuroprotective selective 
oestrogen receptor modulators (SERMs) and phytoestrogens which may act as 
selecetive oestrogen enzyme modulators (SEEMs). Considering the reported 
estrogenic nature of formononetin and results from this research, which demonstrated 
inhibition of neuroinflammation by the compound, the role of oestrogen receptors in its 
anti-inflammatory activity in the microglia was explored and proven.  
The potential of formononetin in neurodegenerative disorders, either as a therapeutic 
entity in its own right, or as a chemical scaffold for producing novel therapeutic 
compounds, depends on the ability to cross the blood-brain barrier (BBB) and act in 
the brain. Although this study clearly demonstrated neuroprotective activity for 
formononetin in vitro, its therapeutic potential will be further enhanced with 
investigations,which would provide evidence of BBB permeation.  
A major limitation with oestrogenic compounds is their tendency to induce proliferation 
of certain cancer cells, especially breast cancer cells. In fact, some studies have aimed 
to establish the potential effects of formononetin on breast cancer cells. A separate 
line of investigation was initiated in the research group to provide further information 
on the question of whether formononetin could induce proliferation of human breast 
cancer cells and ovarian cancer cells (Figure 5.1). 
 98 
 
 
Figure 5.1 Proposed mechanism of action of formononetin in LPS-activated BV2 
microglia 
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5.2. Conclusion  
These investigations have provided an enough evidence to conclude that 
formononetin inhibits neuroinflammation through a dual molecular targeting of NF-B, 
and possibly MAPKs signalling pathways in BV2 microglia that have been stimulated 
with LPS. Also, for the first time this thesis demonstrates a potential link between 
activation of ERβ and inhibition of NF-𝜅B-mediated neuroinflammation by 
formononetin. 
.
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